



Faculty of Health Sciences 
Production and purification of recombinant C-terminal 
truncated pro-Matrix Metalloprotease-9 
 
Fatema Rahman 
Master thesis in Biomedicine  







Abbreviations .............................................................................................................................. 7 
Abstract ....................................................................................................................................... 9 
Introduction .............................................................................................................................. 10 
Extracellular Matrix (ECM) ................................................................................................................ 10 
Molecular composition of the ECM .................................................................................................. 10 
Versatile environment of the ECM ................................................................................................... 11 
MMPs and MMP family members .................................................................................................... 12 
MMP-2 and MMP-9 .......................................................................................................................... 15 
MMP-9 gene.................................................................................................................................. 16 
MMP-9 domains structure and their function .............................................................................. 16 
Amino acid sequence of pre-proMMP-9 ...................................................................................... 20 
Monomer, oligomers, complexes and truncated forms of MMP-9 .............................................. 21 
Cell expression of MMP-9 ............................................................................................................. 22 
MMP-9 expression, synthesis and activation ............................................................................... 22 
MMP-9 expression regulatory mechanisms ................................................................................. 26 
MMP-9 substrates ......................................................................................................................... 30 
The role of MMP-9 in diseases ...................................................................................................... 31 
Baculovirus ........................................................................................................................................ 32 
Baculovirus life cycle ..................................................................................................................... 32 
Gene transcription of Baculovirus ................................................................................................ 34 
Baculovirus as expression vector .................................................................................................. 35 
Sf9 insect cells ................................................................................................................................... 35 
Aim of the study ................................................................................................................................ 36 
Materials and methods .............................................................................................................. 37 
Materials ........................................................................................................................................... 37 
Chemicals and reagents ................................................................................................................ 37 
Kits list ........................................................................................................................................... 38 
Buffers and solutions used for the different methods ................................................................. 38 
Antibiotics ..................................................................................................................................... 43 
Antibodies ..................................................................................................................................... 43 
Primers .......................................................................................................................................... 43 
2 
 
Insect cells and growth media ...................................................................................................... 44 
Instruments and software ............................................................................................................. 45 
Methods ............................................................................................................................................ 46 
Site-directed Mutagenesis ............................................................................................................ 46 
Dpn I Digestion of the Amplicon (Amplified product) .................................................................. 50 
Transformation of XL1-Blue supercompetent bacteria ................................................................ 51 
QIAprep Spin Miniprep Kit Protocol ............................................................................................. 51 
Determining the purified pDONR-MMP-9ΔH-HPX DNA concentration and yield ........................ 53 
PCR-based DNA sequencing .......................................................................................................... 54 
BaculoDirect™Baculovirus Expression System .............................................................................. 56 
Agarose Gel electrophoresis ......................................................................................................... 58 
Staining with GelRed ..................................................................................................................... 59 
Sf9 insect cells culture ................................................................................................................... 59 
Viable Cells counts using Trypan Blue ........................................................................................... 60 
Transfection of Sf9 cells ................................................................................................................ 61 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) .................................... 63 
Gelatin zymography ...................................................................................................................... 64 
Protein purification by Gelatin Sepharose Chromatography ....................................................... 66 
Concentration of purified proteins and removal of impurities with molecular size less than 10 
kDa ................................................................................................................................................ 67 
Size exclusion purification ............................................................................................................. 68 
Mass spectrometry ....................................................................................................................... 69 
Western blot analysis .................................................................................................................... 70 
Results and Discussions .............................................................................................................. 73 
Generating a truncated variant of proMMP-9, the proMMP-9ΔH-HPX ........................................... 73 
Transformation of site directed mutagenesis product into XL1-Blue supercompetent bacteria and 
Sequencing ........................................................................................................................................ 74 
Generation of a recombinant Baculovirus DNA vector by Gateway LR recombination reaction ..... 76 
Transfection of Sf9 insect cells with recombinant linear Baculovirus DNA ...................................... 78 
Protein purification by Gelatin Sepharose Chromatography ........................................................... 81 
Identification of the types of protease produced by the transfected Sf9 cells ................................ 83 
Identification of proMMP-ΔH-HPX by Western blot......................................................................... 85 
SDS-PAGE of partly purified concentrated proMMP-9ΔH-HPX protease ......................................... 88 
Western blot analysis of the partly purified concentrated proMMP-9ΔH-HPX sample ................... 89 
3 
 
 .......................................................................................................................................................... 90 
Pufication of MMP-9ΔH-HPX proteinase by Gelatin Sepharose Chromatography with an extra 
washing step ..................................................................................................................................... 90 
Determining the sizes of proteases removed by additional purification step.................................. 92 
Accurate determination of the molecular weight of proMMP-9ΔH-HPX protease bands ............... 94 
Identification of MMP-9 derived peptides in the proMMP-9ΔH-HPX sample by MS/MS ................ 95 
Gelatin Sepharose Chromatography with a pre-elution step ......................................................... 100 
SDS-PAGE analysis of proteases purified with a pre-elution purification step ............................... 101 
 ........................................................................................................................................................ 102 
Size exclusion chromatography for purification of the 48 kDa proMMP-9ΔH-HPX protease ........ 102 
Determination of the separation properties of Sephadex G-75 column .................................... 102 
Concluding remarks ................................................................................................................. 108 
Future prospective ................................................................................................................... 108 
References: .............................................................................................................................. 109 

































The present work was performed at the Tumour Biology Research Group, Institute of Medical 
Biology, University of Tromsø from August 2014-January 2015 and from January 2016-May 
2016. 
First and above all, I praise Allah, the almighty, for giving me the strength and opportunity to 
carry on this project and granting me the capability to proceed successfully. I also grateful for 
his blessing with guidance and assistance of many great people in giving the shape of this 
current thesis.  
I express my deepest regards and gratitude to my main supervisor Assistant Prof. Gunbjørg 
Svineng for her sincere effort, guidance, critical comments and patience throughout the whole 
stages of bringing this project into light. My sincere gratitude goes to my co-supervisor, Prof. 
Jan-Olof Winberg for his unlimited encouragement, thoughtful guidance, and correction of the 
thesis. I have been extremely lucky to have such kind supervisors who really cared so much 
about my work, and responded to any questions and queries that I had. 
I want to express my deep thanks to my esteemed Eli Berg for her constant support in 
laboratory work as well as her additional care of my health. I will never forget her such 
motherly responsibilities of making dry food for me in pregnancy period while conducting the 
experiment in the lab. She was inspiration, energy and full of happiness for me throughout the 
research work. 
I must be indebted to Senior Researcher Nabin Malla for his guidance, support, and valuable 
suggestions in conducting the critical laboratory work. I would like to thank all members of 
the Tumour Biology Research Group for their cordial support and cooperation and friendly 
attitude. 
I am grateful to all of my friends specially Yakubu Abudu Princely for his help and suggestions 
relating to the studies. 
I cannot finish without thanking my two beloved boys Saifan and Saihan. Their unlimited 
dedication and lovely contribution really helped me to make this effort successful. You two are 
my soul also belong to this achievement. Love both of you so much papa. 
I would especially like to express my deepest gratitude to my younger sister, Farhana Rahman, 
for being around me in taking all family responsibilities throughout writing period of this 
thesis. Words will not be enough to express my love for her. 
Last but not least, I would like to express my very profound gratitude to my husband for his 
unfailing support and continuous encouragement throughout my years of study. His 
unmeasurable dedication and inspiration always boosted my confidence.  This accomplishment 
would not have been possible without you my handsome hubby. Love you so much.  








BSA                        Bovine serum albumin 
DMSO                     Dimethyl sulfoxide 
DTT                         Dithiothreitol 
ECM                        Extracellular Matrix 
HEPES                    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP                        Horse radish Peroxidase 
kDa                         Kilodalton 
MMP                       Matrix metalloprotease 
MMP-9ΔH-HPX      Hinge and hemopexin truncated MMP-9 
PAGE                     Polyacrylamide gel electrophoresis 
PCR                        Polymerase chain reaction 
SDS                        Sodium dodecyl sulfate 
TBST                      Tris-buffered saline -Tween 


























Matrix metalloprotease-9 (MMP-9) consists of an N-terminal signal peptide, a pro-
domain, followed by the catalytic domain that comprises of three fibronectin-like 
repeats, and a unique hinge region that connects the N-terminal to the C-terminal 
hemopexin-like domain. Naturally, MMP-9 is secreted by a wide number of cell types. 
In this study, we produced a truncated proMMP-9 lacking the C-terminal hemopexin 
domain and the hinge region. We used Sf9 insect cells and the BaculoDirectTM 
Baculovirus expression system. To produce this truncated variant of MMP-9, site 
directed mutagenesis was used to generate a point mutation that resulted in a stop 
codon. We designed two mutagenic primers containing the desired mutation. We 
changed G to T in the codon GAA code for the amino acid glutamate at the position 
448 using a Gateway compatible vector pDONR221-MMP-9.  The amino acid E-448 
is located just after the catalytic domain and in the start of the hinge region. The 
mutated proMMP-9ΔH-HPX and the full length proMMP-9 were cloned into the 
Baculovirus genome and by transfecting Sf9 cell with these clones, we produced 
proMMP-9 and proMMP-9ΔH-HPX. 
Both proMMP-9 and proMMP-9ΔH-HPX were purified by employing the Gelatin 
Sepharose Chromatography and Size Exclusion chromatography. Gelatin 
zymography revealed the gelatinolytic activity and molecular size of the truncated 
proMMP-9. The molecular size of the truncated form of proMMP-9 was estimated to 
be approximately 48 kDa by gelatin zymography, and the purity of the produced 
protease by SDS-PAGE and Coomassie staining. The identity of the protease was 






Extracellular Matrix (ECM) 
A complex network of macromolecules presents within all tissues and organs called 
extracellular matrix (ECM). This non-cellular component provides not only necessary 
physical support for the cellular constituents but also launch significant biochemical 
and bio-mechanical stimuli required for tissue morphogenesis, differentiation and 
haemostasis (Frantz et al., 2010). Each tissue has ECM with a unique cellular 
composition. Basically, the ECM is composed of water, proteins and polysaccharides. 
Variation in the relative amount of the different macromolecules and their way of 
organization in the ECM give rise to an excellent diversity of forms capable of adapting 
in the functional requirements of the particular tissue. ECM can generate biochemical 
and mechanical properties of each organ, such as its tensile and compressive 
strength, and elasticity by changing into calcified form to make bone or teeth, 
transparent matrix of cornea, basal lamina between epithelial and connective tissue 
(Alberts B., 2002). 
  
The common thinking used to be that ECM serves mainly for the physical structure of 
the tissue. However, recent studies revealed its active and complex role in regulating 
the cell behaviour by influencing their survival, development, migration, proliferation, 
shape and function (Alberts B., 2002). ECM directs necessary morphological 
organization and physiological function by binding growth factors (GFs) and interacting 
with cell surface receptors to stimulate signal transduction and regulate gene 
transcription (Frantz et al., 2010) (Fig.1). 
 
Molecular composition of the ECM 
The ECM is composed of two main classes of macromolecules; proteoglycans (PGs) 
and fibrous proteins that are secreted locally and assembled into an organized network 
in close contact with the surface of the cell that produced them (Jarvelainen et al., 
2009; Schaefer and Schaefer, 2010). PGs are spectacularly complex macromolecules 
that each contain a core protein to which various forms of glycosaminoglycan chains 
(GAGs) are covalently attached (Hay, 1991). PGs in connective tissue form a highly 
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hydrated gel like ground substance in which the fibrous proteins such as collagen, 
elastin, fibronectin and laminin are attached (Vakonakis and Campbell, 2007).  
 
Versatile environment of the ECM 
ECM dynamics are a feature of tissues undergo radical remodelling and this can result 
from the changes of altered ECM composition by synthesis or degradation of one or 
more ECM components. One of the most significant enzyme families involved in ECM 





Figure 1. Schematic presentation of major ECM components and their 




MMPs and MMP family members 
MMPs are collectively known as matrixins and are zinc-dependent multi domain 
endopeptidases (Dufour et al., 2008b; Yabluchanskiy et al., 2013). They play a crucial 
role in morphogenesis, tissue repair, wound healing and tissue remodeling in normal 
physiological processes and also in response to various injuries (Nagase et al., 2006). 
These proteases are known to cleave all structural elements of ECM, as well as non-
ECM substrates (Massova et al., 1998; Nagase et al., 2006; Yabluchanskiy et al., 
2013).  
 
 Previously mentioned, the ECM represents a complex and dynamic structure made 
of different types of proteins molecules which actively interact with cells. It also serves 
as a reservoir for many biologically active molecules such as cytokines, proteases, 
growth factors, chemokines, cell factors or growth factor receptors (Sheikh, 2013). 
 
Different types of proteases, for example plasmin and cathepsins, are associated with 
ECM degradation but the most significant enzymes are considered to be MMPs 
(Massova et al., 1998; Nagase et al., 2006). The breakdown of ECM molecules or cell 
surface molecules changes cell-matrix and cell-cell interactions. The release of 
biologically active molecules, for example growth factors that remain attached to the 
ECM, makes them available for cell receptors (Jarvelainen et al., 2009) and hence 












To date, 25 family members of MMPs have been identified in vertebrates. Among 
them, 23 members including duplicated MMP-23 genes are found in human (O’Connell 
et al., 1994). MMPs are also found in Sea urchins (Hobeika et al., 2007b) and plants 
like Arabidopsis (Ra and Parks, 2007).  
 
Historically, MMPs were named depending on their preferential action on matrix 
components. Currently, a classification based on their domain organization is 
favoured. MMPs are classified into four groups; archetypal MMPs, matrilysins, 
gelatinases and furin-activated MMPs. Their typical structure consists of a signal 
peptide (SP), a prodomain, a catalytic domain, a hinge region, and a hemopexin like-
domain (Gong et al., 2014) (Fig 3). 
 
Figure 2. Mode of action of the matrix metalloproteases in the ECM. (A) MMPs can 
affect cell migration by changing the cells from having an adhesive to a non-adhesive 
phenotype, and also by degrading the ECM. (B) MMPs are able to alter ECM 
microenvironment affecting cell proliferation, apoptosis, or morphogenesis. (C) MMPs 
may modulate the activity of biologically active molecules such as growth receptors and 







Figure 3. Domain structure and classification of mammalian MMP family members. 
The archetypal MMPs include collagenases, stromelysins and others based on their 
substrate specificities. Matrilysins lack the hemopexin domain and hinge region. 
Gelatinases have fibronectin repeats (Fn) in their catalytic domain. Furin-activated 
MMPs contain a furin (Fr) recognition motif and this type MMPs include three secreted, 
six membrane type (MT) and two unusual type II transmembrane MMPs. According to 
attachment to the plasma membrane, MT-MMPs are divided into type I transmembrane 
MMPs and glycophosphatidylinositol (GPI) MMPs. Type II transmembrane MMPs do not 
have the cysteine switch motif in the pro-domain, and the hemopexin domain, instead 
they have a cysteine array (Cys) followed by an immunoglobulin-like (IgG-like) domain 
(Gong et al., 2014). 
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All MMPs, except the two Matrilysins (MMP-7 and MMP-26) and MMP-23 constitute a 
hemopexin-like domain and a hinge region. The catalytic domain in MMP-2 (gelatinase 
A) and MMP-9 (gelatinase B) differs from that of the other MMPs as the domain also 
contain a module of three fibronectin-type II-like repeats. MMP-11 and MMP-28 
possesses a furin motif for recognition by furin-like serine proteases. This motif is also 
present in MMP-21 and in membrane-type MMP (MT-MMP). There are eight different 
MT-MMPs, four contain a C-terminal type 1 transmembrane domain, two contain a C-
terminal GPI anchor while the last two MMP-23 A and MMP-23B contain at the N-
terminal a type II transmembrane domain and instead of the C-terminal HPX domain 
these two MMPs contain a cysteine array and an immunoglobulin-like domain (Gong 
et al., 2014) (Fig.3).  
 
MMP-2 and MMP-9 
The two MMPs, MMP-2 and MMP-9, are known as gelatinases due to their potent 
gelatin-degrading capacity (Cauwe and Opdenakker, 2010). They are the closest 
homolog in this family and share four highly homologous domains. The main structural 
difference between the two gelatinases is the presence of an extremely O-glycosylated 
hinge region in MMP-9 (Opdenakker et al., 2001b; Van den Steen, 2006).  
 
Degradation properties of MMP-2 and MMP-9 are closely associated with multiple 
pathologies, including cancer, bone diseases, inflammatory disorders and vascular 
alterations such as atherosclerosis, aortic aneurysm and myocardial infarction (Hu et 
al., 2007) and this has in particular attracted biomedical investigators to study MMP-9 
to great extent. A long term study on MMPs revealed their importance in the biomedical 
investigation. From the figure 4, it can be seen that since 1995 the study on gelatinases 
has grown exponentially. Within the MMPs Pubmed literature, gelatinases were 
overrepresented and MMP-9 was the top studied with more than 50% of all MMPs 









MMP-9 gene  
The human MMP-9 gene is located on the long arm (q) of chromosome 20 between 
positions 11 and 13. This gene consists of 7654 base pair (Homo sapiens Annotation 









MMP-9 domains structure and their function  
MMP-9 is synthesized as an inactive zymogen referred to as ''proMMP-9 (92-kDa)''. 
The domain structure of proMMP-9 consists of an NH2-terminal pro-domain, a catalytic 
domain, a hinge domain and a COOH-terminal hemopexin-like domain (Fig. 6A). At 
the very N-terminal of preproMMP-9 a signal peptide is located. In the initial phase of 
translation, this signal peptide directs the growing polypeptide to the endoplasmic 
reticulum. Next to the signal peptide there is a hydrophobic pro-peptide domain which 
 
Figure 4. Evolution of the PubMed literature on all MMPs, MMP-2 and MMP-9. 
MMP-2 and MMP-9 were the most studied MMPs in the past decades. MMP-9 
reached top at more than 50% of all MMP literature (Vandooren et al., 2013).  
 
 
Figure 5. Location of human MMP-9 gene on the chromosome no 
20. An arrow showing the position of MMP-9 gene. Modified from Homo 
sapiens Annotation Release 107, GRCh38.p2 (NCBI). 
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consists of approximately 80 amino acids including a highly conserved “cysteine 
switch” sequence (PRCGXPD). This interacts with the catalytic zinc atom through its 
side chain thiol group (Massova et al., 1998) and maintain the inactive form of the 






















MMP-9 has a unique domain inserted into the catalytic domain called fibronectin-like 
module consisting of three FnII like repeats. This module is homologous to the type II 
module of fibronectin. The fibronectin-like module is essential for MMP-9 in binding to 
 
 
Figure 6. Illustration of domain arrangement of preproMMP-9. A.  Besides signal 
peptide in N-terminal region, three domains are the pro-domain, catalytic domain, and 
the hemopexin-like C-terminal domain connected to the catalytic domain via a flexible 
hinge region. Inactive MMP-9 or zymogens contains cysteine switch in the pro-domain 
which must be cleaved to activate the protease. The catalytic domain has three repeats 
of fibronectin type II module help in binding gelatin. β-propeller structures in the C-
terminal domain provide a substrate or TIMP recognition site. B. Crystal structures of 
the N-terminal domains of proMMP-9. The N-terminal pro-peptide (green), three 
fibronectin type-II repeats (blue), and a catalytic domain (red). A zinc-containing active 
site in the catalytic domain (grey sphere) (Van den Steen, 2002a). The hinge region 
(dashed line) contains 64 residues. Crystalization of hinge region in proMMP-9 
separately or together with other protein domain has been found difficult due to its built-
in bend structure and also its elasticity properties. This region connects the N-terminal 
domain to the C-terminal hemopexin domain which consists of four propeller blades 
(cyan) (PDB code: 1ITV) (Cha, 2002; Elkins, 2002  ). C. The catalytic and structural zinc 
ions are shown as light grey spheres. The structural calcium ions are shown as yellow 
spheres (PDB code: 1L6J).  
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denatured collagen (i.e. gelatin) (O'Farrell and Pourmotabbed, 1998). A metal binding 
site contain a zinc-binding motif that bind catalytic zinc (Fig. 6B and C). The catalytic 
domain of MMP-9 has additional binding sites for a structural zinc ion and 2-3 calcium 
ions. These ions are required for the enzymes stability and expression (Fig. 6C). The 
second zinc ion is located in the catalytic domain around 12 Å away from the catalytic 
zinc ion (Gupta, 2012). 
 
An elongated linker between the catalytic and hemopexin-like domain is known as the 
hinge region. This hinge region is around 64 amino acids long and is rich in proline, 
serine and threonine residues. Previously, the hinge region used to also be called the 
collagen type V-like domain due to its homology to collagen type V. Later, it was found 
that the homology with collagen type V was rather low because of its high proline 
content and the name was no longer used (Wilhelm et al., 1989). The hinge region is 
an independent protein domain and rich in O-linked glycans and henceforth has also 
been called the O-glycosylated domain or OG domain (Van den Steen, 2006). The 
structure of hinge region is unique and important for substrate binding. A number of 
studies revealed that this domain is crucial for correct MMP-9 function. It has been 
known that TIMP-1 binds to the C-terminal part of proMMP-9 (Murphy et al., 1991; 
Oconnell et al., 1994). The hinge region influences the binding of TIMP-1 to the 
hemopexin domain. Deletion of the hinge region leads to a 10-fold decreased affinity 
for TIMP-1 and interrupt internalization by the cargo receptors low density lipoprotein-
related protein (LRP-1(CD91)) and LRP-2 (megalin) (Van den Steen, 2006). In 
addition, deletion of this domain also reduces MMP-9-mediated cell migration (Dufour 
et al., 2008a), and lowers the efficiency of degradation of large gelatinous substrates 
to great extent (Vandooren et al., 2011). Furthermore, structural studies revealed that 
this O-glycosylated domain is necessary for proper orientation and for flexibility of 
proMMP-9 (Rosenblum et al., 2007; Van den Steen, 2006). 
 
The hemopexin like domains in MMPs have structural homology with hemopexin 
protein that are profoundly present in plasma. Human MMP-9 shares only 25–33% 
amino acid identity with hemopexin domains from other MMPs (Dufour et al., 2011). 
Hence revealed the uniqueness of MMP-9 within the MMP family. The C-terminal 
hemopexin domain of MMP-9 forms a propeller with four blades where the first blade 
is linked to the fourth one by means of a disulfide bridge (between Cys516 and 
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Cys704) (Fig.6-7). This covalent linkage is critical for interaction with substrates and 
binding to cell surface receptors (Fouad A. Zouein, 2015). 
 
 
Until now, four functions of the hemopexin domain in MMP-9 have been recognized. 
Those are (i) interaction with substrates, (ii) binding to inhibitors, (iii) binding to cell 
surface receptors and (iv) induction of auto-activation. The substrates known to bind 
to HPX of MMP-9 are gelatin, collagen type I, collagen type IV, elastin and fibrinogen 
(Burg-Roderfeld et al., 2007; Roeb et al., 2002), and their affinity is higher for full-
length proMMP-9 than for activated MMP-9 without pro-peptide (Burg-Roderfeld et al., 
2007). The HPX domain also interacts with the inhibitors TIMP-1 (Goldberg et al., 
1992) and TIMP-3 (Butler et al., 1999), beside binding to several cell surface 
molecules such as LRP-1, LRP-2 (Van den Steen, 2006), DNA repair protein (Ku) 
(Monferran et al., 2004), Cell surface glycoprotein (CD44) and Reversion-inducing 
cysteine-rich protein with Kazal motifs (RECK) (Dufour et al., 2008a; Sternlicht and 
Werb, 2001). In addition, HPX like domain has a role in proper orientation of MMP-9 
through the hinge region and in localization of MMP-9 to the membrane by the 
interaction with the Ku70/Ku80 heterodimer (Monferran et al., 2004). Furthermore, the 
 
Figure 7. The mechanism of inactivation and cystein bridges of proMMP-9. The 
proMMP-9 sequence contains 17 cystein residues in which a highly conserved cysteine 
switch sequence (PRCGVPD) of pro-domain interacts with the catalytic zinc atom through 
its side chain thiol group to maintain inactive form. Each of the three fibronectin repeats 
forms two cysteine bridge whereas HPX domain possess one cysteine bridge. Modified 
from (Vandooren et al., 2013). 
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HPX domain is found to mediate dimerization or multimerization by noncovalent, and 
mainly by hydrophobic, interactions at the fourth blade of the domain (Cha et al., 
2002b). Recently, HPX domain is discovered to take part in proMMP-9 autocatalysis 
by binding of heme with hemopexin domain and thereby initiate activation of the 
enzyme. β-hematin interacts with the MMP-9 HPX domain and bring about 
autocatalytic processing of proMMP-9 (Geurts et al., 2008). Similarly, a complex of 
MMP-9 with a chondroitin sulfate proteoglycan (CSPG) is secreted by a macrophage 
cell line (THP-1) (Winberg, 2000) and is found to be covalently linked via the HPX 
domain (Winberg et al., 2003).  
 
Amino acid sequence of pre-proMMP-9 
The preproMMP-9 consists of total 707 amino acid residues in which 19 amino acid 
residues in signal peptide, 166 amino acid residues in FnII module and 187 amino acid 
residues in HPX domain (Fig.8). The domains indication in the figure 8 was done 






Monomer, oligomers, complexes and truncated forms of MMP-9 
Besides the monomeric form, MMP-9 is found to forms oligomeric structures and 
complexes with other molecules, as well as low-molecular weight truncated forms. It 
is postulated that one intermolecular cysteine bridge is required to form dimer whereas 
two bridges for trimers and so on. MMP-9 is found to form complexes with Neutrophil 
gelatinase-associated lipocalin (NGAL) by covalent linkage (Triebel et al., 1992b).   
Truncated form of MMP-9 is also observed in which different proteases including 
 
Figure 8. Amino acid sequence of preproMMP-9. The sequence of different 
domains was indicated by different colours where Cystein residue s were marked in 
red. The sequence of human preproMMP-9 was taken from the MEROPS database 
(Rawlings et al., 2014) and the domain indication was done based on the information 




MMP-3, kallikrein-related peptidase 7 and meperin-α are involved. MMP-3 generates 
a 65 kDa form of MMP-9 which lacks NH2 -terminal pro-peptide and COOH-terminal 
hemopexin domain (Okada et al., 1992). 
 
Cell expression of MMP-9 
MMP-9 is secreted by a large number of cell types, including neutrophils, Polymorpho-
Nuclear Leukocytes (PMN), keratinocytes, monocytes, macrophages, osteoblasts, 
fibroblasts, endothelial cells, and some malignant tumor cell lines including MDA-MB-
231 breast cancer, HT-1080 fibro sarcoma and A2058 melanoma cell lines, (Mackay 
et al., 1992; Opdenakker et al., 2001c; Van den Steen, 2002b). 
 
MMP-9 expression, synthesis and activation 
Normally, the expression of most MMPs is low in tissue and it is only induced when 
remodelling of the extracellular matrix (ECM) is required (Van den Steen, 2002a). The 
transcription of MMP-9 gene is initiated with the stimulation of various physiological 
factors including cytokines and growth factors. Among these factors are interleukins, 
interferon, Nerve Growth Factor (NGF), Epidermal Growth Factor (EGF), basic 
Fibroblast Growth Factor (FGF), Vascular Endothelial Growth Factor (VEGF), Platelet 
Derived Growth (PDGF), and Tumour Necrosis Factor (TNF-a), Transforming Growth 
Factor (TGF-b), the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN), 
oncogene product, metal ions, reactive oxygen species or hormones. Many of these 
factors induce the expression or activation of c-fos and c-jun proto-oncogene products. 
These products hetero-dimerize and bind to the activator protein-1 (AP-1) sites within 
MMP-9 gene promoters for expression (Jodele et al., 2006). 
 
Actually, the nature of the stimulus and the cell type normally determine which 
transcriptional factors will be involved in MMP-9 gene expression. At the position of –
79 to –73, the AP-1 most likely is to be considered as the most critical binding motif 
for MMP-9 transcriptional activity. Maximal expression of MMP-9 by TNF-α through 
AP-1 requires the association of other transcription factors, such as Sp-1 and NF-κB. 
Sp-1 located at position –558 to –563 and a NF-κB consensus sequence located at 






In MMP-9, the transcription factors ETS (Erythroblast Transformation Specific) 
recognize the purine rich GGAGAGGAAG motif located at position -540 and act 
synergistically with NF-κB, SP-1 and AP-1 binding sites when cells are activated by 
the Ras oncogene (Gum et al., 1996). Furthermore, Epidermal Growth Factor (EGF) 
can also potentiate MMP-9 promoter activation through AP-1 in breast tumor cell lines 
(Watabe et al., 1998).  
However, after transcription the MMP-9 mRNA translated into preproMMP-9 where 
the pre-domain directs the polypeptide chain to the endoplasmic reticulum where the 
pre-domain is cleaved off. N-glycosylation occur co-translationally on the nascent 
protein whereas O-glycosylation occur during later post translational stages in the 
Golgi apparatus and trans-Golgi when MMP-9 proteins are already folded (Van den 
Steen et al., 1998). In the ER of the cell, 85 kDa MMP-9 is altered into 89 kDa 
intermediately glycosylated form and at the end of glycosylation it becomes into 92 
kDa after passing through the Golgi complex (Hanania et al., 2012; Olson et al., 2000). 
Glycosylation is found to have higher impact on the enzyme catalytic efficiency and 
oligomerization, also on the intra- and inter-domain flexibility (Fouad et al., 2015). In 
this process of synthesis, proMMP-9 acquires its tertiary structure that is identified by 
O- glycosylation in the hinge region and seven disulfide bridges (Fig. 7).  
 
 
Figure 9. The principal binding motifs of transcription factors in the promotor 
region of MMP-9. Open boxes denote cis-elements: NFkB, transcription factor NFkB 
binding site; SP1, transcription factor SP1 binding site; AP1, transcription factor AP1 
binding site; TIE, transforming growth factor β1 inhibitory element, TATA box. Closed 




Disulfide bond formation between two cystein residues of MMP-9 is the most well-
known post translational modification. The MMP-9 translated sequence contains 19 
cysteine residues (Fig. 6-8) where two of them are located in the signal peptide 
(Wilhelm et al., 1989). Upon cleavage of signal peptide during translation, proMMP-9 
remains with 17 cysteine residues (Hibbs et al., 1985). Seven disulfide inter-domain 
bridge is formed by 14 cysteine residues. Six of these disulfide bonds are to be found 
within the fibronectin-type II repeats of the catalytic domain and are significant for 
proMMP-9 secretion. (Wilhelm et al., 1989; Khan et al., 2012). The remaining one 
disulfide bond interconnects blade I and IV within hemopexin domain (Cha et al., 
2002a). Out of the rest three cysteine residues, Cys99 in the pro-domain interact with 
the zinc ion of catalytic domain and thereby keeps the enzyme inactive. The remaining 
two Cys468 and Cys674 are found within the O-glycosylated and hemopexin domains 
respectively. It is assumed that these two residues might be involved in intermolecular 
interaction and MMP-9 multimer formation (Van den Steen et al., 2006). 
Activation of pro-MMPs requires the removal of the pro-region by a mechanism called 
cystein switch. This mechanism depends on a conformational change which results in 
breaking the bond between the catalytic zinc and cysteine residue in the pro-domain 
and enables water to interact with the zinc ion in the active site of MMP-9. However, 
the activation process is accomplished through three different mechanisms: (i) 
elimination of the pro-domain by direct cleavage by another endoprotease (ii) chemical 
alteration of the free cysteine followed by autoproteolysis (iii) allosteric re-conformation 
of the pro-domain (Busti et al., 2010; Ra and Parks, 2007). Intracellular component 
such as S-nitrosylation or extracellular proteases including tissue kallikrein, plasmin, 
urokinase-type plasminogen activator, MMP-1, MMP-2, MMP-3, and MMP-7 can all 





Autocleavage of the pro-peptide in vitro by treating with organo-mercurial compounds, 
urea, SH reactive reagents, and chaotropic agents, detergents such as SDS which 
chemically modify the pro-MMP structure can result in auto-activation of MMP-9. 
Further, an investigation of gelatinase activity of MMP-9 in human placenta in situ 
suggested that the proMMP-9 is enzymatically active with presence of its N-terminal 
pro-peptide with 10-fold lower activity than fully active enzyme (Bannikov et al., 2002). 
Thus, through an alternative mechanism involving allosteric activation, pro-MMP-9 can 
be activated without proteolytic process of the pro-peptide. In this mechanism, binding 
of proMMP-9 to gelatin or collagen IV, the pro-peptide is distorted away from the active 
site leaving an open active site that can bind and process substrates. Removal of the 
binding molecules causes a reversion into an inactive proenzyme (Hadler-Olsen et al., 
 
Figure 10. MMP-9 expression, synthesis and activation.1. N-glycosylation occur co-
translationally at the pro and catalytic domains of proMMP-9. 2. MMP-9 is processed 
through Golgi complex and acquire tertiary structure. 3. Activation of MMP-9 either by 
intracellular components or extracellular components. 4. Proteolytic activity on its 
substrates such as various cytokins and trancription factors. 5. Binding to the site in the 
promotor region, Trans-activators stimulate further MMP-9 expression. Permission 




2011). Once MMP-9 is activated, it proteolytically processes a wide range of 
compounds including multiple pro-inflammatory cytokines such as TNF-α, IL-1β, and 
IL-8. These compounds bind to their receptors and thereby activate them. The 
activation of the receptors triggers an intracellular signalling cascade that recruits 
various trans-activators to the binding sites at the promotor region of MMP-9. This in 
return stimulates to further MMP-9 expression (Fouad et.al., 2015) (Fig.10). 
 
MMP-9 expression regulatory mechanisms 
According to past and recent studies, MMP-9 activity is regulated at various levels. A 
variety of signaling pathways that stimulate or suppress the transcription of the MMP-
9 gene was considered to be the first level of regulation. Second, MMP-9 is regulated 
at mRNA level and the level of translation into the pre-proenzyme. The final amount 
of preproMMP-9 is determined by degradation of MMP-9 mRNAs and several 
signaling pathways are able to stimulate to do so. More importantly, microRNAs were 
also observed to involve at this level of regulation. Secretion of proMMP-9 from 
secretory vesicles of neutrophils is might be a third level of regulation. Another level 
of regulation occurs after secretion, where proMMP-9 needs to go through various 
mechanisms in the extracellular milieu for activation. Finally, the activity of MMP-9 is 
regulated by various MMP-9 inhibitors (Vandooren et al., 2013). The mechanism of 
MMP-9 regulation is described below:  
 
Regulation of MMP-9 gene transcription 
At the transcriptional level, MMP-9 is regulated by a number of pathways including the 
MAPK pathway, the Smad pathway, the NIK/NEMO/IKK pathways, the STAT 
pathways and nuclear receptor pathways. However, MMP-9 is mainly regulated by 
ERK1/2 member of MAPK pathways with the interferences of many essential 
regulatory elements that are mentioned in the previous section 1.5.6. At the initial level 
of transcription, most of the transcription factors or regulatory elements interfere with 
the basic MMP-9 promotor activation machinery in order to suppress or repress of 
MMP-9 expression. The binding of NF-kB and AP-1 factors in the promoter region are 
often found to suppress MMP-9 transcription. On the other hand, a complex SP2/KLF6 
binding to the Sp1 site in the MMP-9 gene promotor is found to repress MMP-9 
expression. However, some other factor including Kiss1 (Lee and Welch, 1997) RECK 
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(Takagi et al., 2009) EGR-1 (Bouchard et al., 2010) were also documented to interfere 
promotor activity of MMP-9 (Fig.11). In addition, polymorphisms in the gene promoter 
sequences of MMP-9 have been observed to be associated with the regulation of gene 
expression (Zhang et al., 1999). The presence of microsatellite d(CA) repeats in the 
MMP-9 promoter sequence considerably impairs the activity of the MMP-9 promoter 
in several cell types (Shimajiri et al., 1999). The reason might be the close localization 
to the transcriptional start site of MMP-9. 
 
In macrophages, the expression of MMP-9 was found to be induced directly by both 
MMP-1 and MMP-3 by triggering the release of TNF-α. TNF-α induces the expression 
of COX-2 and PGE2 secretion. Binding of PGE2 to EP4 in the cell membrane 
stimulates MMP-9 production through MAPK/ERK1/2 signaling (Steenport et al., 
2009). Several neurotransmitters and hormones have role in the induction of MMP-9 
expression. For example, histamine can induce MMP-9 production in human 
keratinocytes by signaling through the histamine H1 receptor (H1R). Histamine-
induced MMP-9 contribute to the destruction of type IV collagen which is present in 
the basement membrane of healthy skin (Harvima, 2008). Adrenalin was also 
observed to induce the production of MMP-9. In a human colon carcinoma cell line, 
supplementation with adrenalin resulted in increased levels of MMP-9 (Wang et al., 
2011). Additionally, noradrenaline induces MMP-9 expression in the mouse 
neuroendocrine hypothalamus and in nasopharyngeal carcinoma tumor cells 
(Maolood et al., 2008; Yang et al., 2006). Bile acids were detected to induce MMP-9 
production through binding to nuclear FXR which subsequently binds to the MMP-9 
promoter region and thereby induces transcription (Vandooren et al., 2013). 
 
Epigenetic regulation where a number of mechanisms involve such as histone 
modification, DNA methylation and noncoding RNAs (ncRNAs). Depending on the cell 





et al., 2003) or lower (Estella et al., 2012) expression levels of MMP-9. The expression 
of MMP-9 gene is regulated by DNA methylation. Inhibitors of DNA methylation induce 
MMP-9 mRNA and protein level of MMP-9 (Sato et al., 2003). 
 
 Post transcriptional and post translational regulation of MMP-9 
After transcription, the final amounts of mRNA are determined by stabilization and 
destabilization regulation upon binding of noncoding (ncRNAs) RNAs and RNA-
binding proteins to the mRNA cis-acting elements (Wu and Brewer, 2012). A dynamic 
complex of mRNA with proteins called ribonucleoprotein complexes (mRNPs) are 
found to act as mediators of post-transcriptional events such as capping, splicing, 
quality control and trafficking (Hieronymus and Silver, 2004). The 3'UTR of MMP-9 
gene was found to be a crucial region for post-transcriptional regulation. A study of 
 
Figure 11. Regulation levels of MMP-9.  MMP-9 is regulated by several pathways at 
transcriptional level. Various regulatory elements, including AP-1 and NF-kB are 
involved in transcription level by binding to the promoter region of MMP-9. Dynamic 
mRNP complexes control mRNA degradation and stabilization after transcription with 
the help of nucleolin. The secreted proMMP-9 is activated into MMP-9 by different 
proteases such as MMP-3, plasmin and trypsin. Activated MMP-9 binds to several cell 
surface molecules, e.g. Ku, LRP1/2, integrins and CD44 to form an MMP-9 cell surface 
complex (Vandooren et al. 2013) 
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RNA or protein interaction showed that the elevated binding of nucleolin to the 3'UTR 
of the MMP-9 transcript might be significant for the increased efficiency of MMP-9 
translation (Fahling et al., 2005).  
 
Noncoding RNAs are not translated into proteins consist of many other types of RNA. 
Based on function and features, they are numerous. However, only miR-4915q has 
been found to be correlated with the expression of MMP-9 in glioblastoma multiforme 
(GBM) disease (Yan et al., 2011). 
 
Glycosylation event is very crucial in the activities of protein macromolecules and their 
interactions with inhibitors or substrates (Kotra et al., 2002). Unlike other 
glycoproteins, the addition of N-linked oligosaccharides takes place co-translationally 
in the endoplasmic reticulum (ER) together with the folding of MMP-9 (Dwek, 1996). 
These N-linked sugars have been found to be associated with correct protein folding 
(Kotra et al., 2002). O-linked oligosaccharides are sequentially attached by specific 
sugar transferases when the N-glycosylated folded proteins travel to the Golgi 
apparatus and the trans-Golgi (Van den Steen et al., 1998). However, correct folding 
and intramolecular disulfide bonds in the fibronectin domain are a prerequisite for the 
MMP-9 secretion (Arnold and kaufman, 2003). 
 
Regulation of MMP-9 secretion 
Neutrophils do not constitutively produce MMP-9. An inflammatory stimulus is needed 
for MMP-9 secretion (Van den Steen, 2002b). The MMP-9 produced by neutrophils is 
TIMP-1 free and it was demonstrated to be pro-angiogenic. However, a study showed 
that a GTPase like Rab27a co-localize with neutrophil MMP-9, regulating the secretion 
of the MMP-9 (Brzezinska et al., 2008). Secretion of MMP-9 differs with timing 
between macrophages and neutrophils. The mature neutrophils store MMP-9 in 
granules and release it upon stimulation within minutes, while in macrophages, it takes 
several hours as macrophages rely on the process of de novo synthesis of MMP-9 
prior to secretion. MMP-9 is not stored in macrophages but instead directly secreted 




 MMP-9 inhibition 
As mentioned before, MMP-9 is secreted as zymogen where pro-domain coordinates 
with Zn2+ of catalytic domain to suppress the MMP-9 activity. Till now three different 
activation mechanisms of MMP-9 have been identified, those were described earlier. 
Once MMP-9 is secreted, its protease activity is tightly controlled to keep the 
physiological balances in the host. Both monomers and multimers of MMP-9 are 
inhibited by endogenous inhibitor TIMP-1. The main TIMP-1 binding site of proMMP-
9 is located in the hemopexin domain (O'Connell et al., 1994). Olsen et al. also 
reported that proMMP-9 multimers have two high affinity binding sites for TIMP-1, both 
most likely localized in the hemopexin domain (Olson et al., 2000). Polyunsaturated 
fatty acids can efficiently inhibit the activity of MMP-9. A study revealed that Zn2+ 
chelation is not the way of inhibition by fatty acid instead it is linked to the fact of 
mimicking the natural sequence of the pro-domain of MMP-9 (Hu et al., 2005). 
 
Chemical inhibitors such as tetracyclines and chemically modified tetracyclines 
(CMTs) exert diverse inhibitory effect on MMP-9 synthesis and activation. The 
proposed mechanism of action of these inhibitors results from their ability to bind Ca2+ 
and Zn2+ which are required by MMP-9 to maintain its proper conformation and 
hydrolytic activity. By chelating Zn2+ at the binding site in the catalytic domain of active 
MMP-9, leads to disruption of the normal conformation of the protein structure and 




Even though MMP-9 has high activity against denatured collagens (gelatin), it also 
degrades native collagen, elastin, fibronectin, aggrecan core protein, vitronectin, 
laminin (Bourguet, 2012). Besides some mentioned above, the Non-ECM molecules 
including transforming growth factor (TGF)-β (Yu and Stamenkovic, 2000) and 
monocyte chemo-attractant protein (MCP)-3 are also degraded by MMP-9 






The role of MMP-9 in diseases 
MMP-9 has been reported to be associated with many physiological and pathological 
conditions. The ability to degrade ECM and non-ECM components suggest that this 
enzyme can be a potential oncogenic factor for different type of tumour initiation, 













Since uncontrolled MMP-9 activity can easily destroy the network of multidirectional 
communication within cells and tissues, MMP-9 is considered an important regulator 
of tissue homeostasis and the immune response. 
  
An increased expression of MMP-9 is associated with numerous disorders or diseases 
in human body. MMP-9 has been reported to be involved in cardiovascular diseases, 
periodontal disease and it is common with other MMPs in different type of cancers 
including breast cancer, skin and oral epithelial cancer, lung cancer, pancreas cancer, 
 
Figure 12. The role of inflammatory polymorphonuclear leukocyte (PMN)-derived 
tissue inhibitor of metalloproteinase (TIMP)-free MMP-9.  The free MMP-9 degrades 
extracellular matrix (ECM) components such as cytokines, chemokines and growth 
factors. The release and activation of those components initiate tumour and promote 
genetic instability. With permission (Farina and Mackay, 2014). 
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bladder cancer, cervical cancer, ovarian cancer, colorectal, prostate cancer and brain 
cancer (Giraudo et al., 2004; Lamar et al., 2008; Mehta et al., 2003; Roy et al., 2009; 
Sier et al., 2000).  
 
MMP-9 has been found to be associated with numerous pathological processes and 
different domains of MMP-9 has been implicated as prominent players in these 
processes. Therefore, understanding of MMP-9 physiology including structure, 
regulation and activation is crucial in order to design potential inhibitors of MMP-9. To 
date, several studies has been recorded that aimed to explore MMP-9 structure and 
function. The information provided by Protein Data Bank (PDB) shows that in most 
cases an E. Coli. expression system was used to produce recombinant MMP-9 only 
with catalytic domain, which lacked the FnII module. This has been used for X-ray 
crystallization with inhibitors in high through put inhibitory studies. Crystallization of 
entire MMP-9 at a time has been found difficult because of its very long and flexible 
hinge region. Another method Bac-N-Blue TM DNA (Invitrogen) was used to produce 
recombinant proMMP-9 in Sf9 insect cells. Among the proMMP-9 variants produced 
with this method was two deletion variants, one lacks the HPX domain and the other 
lacks both the hinge and the HPX domain (Van den Steen et al., 2006).  In the present 
master thesis, we used BaculoDirect TM Baculovirus expression system and Sf9 cells 
to produce recombinant MMP-9 lacking both the hinge and HPX domains. Before 
describing the potentiality of Baculovirus as a vector for protein expression, a brief 




Baculovirus life cycle  
Baculoviruses are a group of arthropod-specific virus that contain large, circular, 
supercoiled double stranded DNA molecule with a size ranging from 80 to over 180 
kbp and encoding 90 to 180 genes (George, F.R. 2011). The name “Baculovirus” is 
derived from the latin “baculum” meaning the rod‐shaped nucleocapsids which is 230– 
385 nm in length and 40–60 nm in diameter. Baculoviruses predominantly infect insect 
larvae of Lepidoptera (butterflies and moths) along with Hymenoptera (sawflies) and 
Diptera (mosquitoes). The most widely studied Baculovirus is Autographa californica 
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multiple nucleopolyhedrovirus (AcMNPV) for which the complete genome sequence 
has been determined (George, F. R. 2011). AcMNPV has two phenotypes: budded 
virions (BVs) and occluded virions (OVs) (Fig.13). These two types of virions vary in 
their origin and composition of envelopes and their functions in the virus life cycle. 
BVS consists of a single rod shaped nucleo-capsid envelope enriched in virally-
encoded membrane fusion protein GP64. This protein is incorporated into the BV 
particles during virus budding and release. In the later stage of infection, large number 
of occlusion virions (OVs) or polyhedral are formed. The orally infectious OVs are 
enclosed in a para-crystalline matrix forming occlusion bodies (OBs). The major 
component of OVs is occlusion protein polyhedrin which is a virus-encoded protein 
produced by transcriptional activity of the polyhedron gene promoter. This protein 
protects the virus in the natural environments and permits virus particle to survive 
outside of their natural host and thereby allow virions to remain infectious for very long 
period of time. BVs spreads the infection within the insect host while occlusion-derived 








Gene transcription of Baculovirus 
The gene transcription of baculovirus has four phases: immediate early, 
delayed early, late and very late phase. Immediate early genes are identified by host 
transcription factors and viral proteins are not necessary at this stage. Transcription of 
delayed early genes require activation with the products of immediate early genes. 
The delayed early phase is followed by the synthesis of DNA and the late gene 
products of the virus (Hefferon and Miller, 2002).  It is believed that there is a close 
relationship between these two events of DNA synthesis and late gene product of 
virus. The late transcription phase occurs following the initiation of viral DNA 
replication. In this phase nucleocapsid structural proteins including glycoprotein GP64 
are synthesized which play a crucial role in the horizontal infection by infectious BV 
(Whitford et al., 1989). During the very late phase the production of BV is greatly 
reduced. The process of occlusion of nucleocapsids occurs by the very late viral 
 
Figure 13. Bi-phasic AcNPV replication cycle. Upon ingestion, the polyhedra are 
dissolved inside the gut of the larvae to release occlusion derived virions or polyhedral 
derived virus (PDVs). The PDVs then fuse with midgut epithelial cells and enter the 
cell’s nucleus through primary infection. The viral DNA is uncoated and viral 
transcription initiated. The uncoated nucleocapsid are then transported to the plasma 
membrane where they bud from the host cell acquiring an envelope derived from the 
host cell membrane to produce BVs that in turn cause secondary infection. Also, the 
progeny viruses get embedded into OBs which are released from the cell upon cell 
death (Ghosh et al., 2002). 
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protein‐polyhedrin. As occlusion proceeds, fibrillar structures comprising mostly of a 
very late protein p10 (Vanderwilk et al., 1987). 
 
Baculovirus as expression vector 
The massive expression of the very late genes has been exploited to design the vector 
for foreign gene expression based on Baculoviruses. Since early 1980’s this 
expression system has become one of the most popular method for production of large 
quantity of recombinant protein within eukaryotic cells because of safety (not harmful 
to non‐target organisms) and easy handing in the laboratory. Baculoviruses have 
several attractive features including easy manipulation, able to carry large (at least 38 
kb) (Cheshenko et al., 2001) and multiple DNA inserts (Bieniossek et al., 2012). BV 
can also be readily produced and purified at high titers. A Baculovirus expression 
vector (BEV) is a genetically modified recombinant Baculovirus used for the 
expression of a foreign gene. BEVs are sustainable in insect cell culture and 
sometimes in larvae. However, it depends on the Baculovirus genes deleted in the 
process of the recombinant virus generation. In BEVs, the foreign gene coding 
sequence is usually placed under the transcriptional control of viral promoter. This is 
why viral factors are required for the transcription of the foreign gene. The most 
successful strategy for cloning recombinant Baculovirus is the use of a linearized 
parental genome of Baculovirus. The principle of this technique is illustrated in the 
method section.  
 
Sf9 insect cells 
The traditional cell lines for Baculovirus-directed protein expression system are Sf21  
and Sf9 cells. These two cell lines were originally derived from the pupal ovarian cells 
of Spodoptera frugiperda (fall army worm) termed IPLB-Sf-21 cells, with Sf9 cells 
(IPLB-Sf21-AE) being a clonal isolate of Sf21 cells. Sf9 cells are considered a suitable 
host for expression of recombinant protein from Baculovirus expression systems 
because Sf9 cell lines are normally simple to maintain compared to mammalian cell 
lines (O'Reilly et al., 1992). Additionally, Sf9 can grow in serum-free media containing 
amino acids, carbohydrates, vitamins and lipids essential for insect cell growth that 
reduce the effect of rate-limiting nutritional restrictions or deficiencies that are present 
within serum-supplemented media. Serum-free media is also observed to support 
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rapid cell doubling times and permit cell growth to higher densities compare to serum-
supplemented media facilitating higher virus titres or protein yields. Furthermore, the 
eukaryotic-Sf9 Baculovirus expression system has advantages over prokaryotic and 
yeast expression system as recombinant protein expressed in Sf9 cells are post 
translationally modified and thereby producing protein similar to their native 
counterparts (Zhang et al., 1994). 
 
Aim of the study  
The hinge and hemopexin domain have been found crucial for the proper structural 
orientation and function of MMP-9. In order to study their role in MMP-9 function it is 
important to compare a full length version of MMP-9 with a truncated version where 
the hinge and HPX domain are lacking. In the present study, our aim was to produce 
recombinant human proMMP-9-ΔH-HPX protease by Sf9 cells and establish a 
purification protocol. 
 
To reach the goal we performed the following experiments: 
1. Site directed mutagenesis to generate a point mutation introducing a stop codon 
in the hinge region. 
2.  LR recombination reaction for cloning pDONR221- MMP-9ΔH-HPX into the 
Baculovirus DNA. 
3. Transfection of Sf9 cells with the recombinant Baculovirus to produce proMMP-
9ΔH-HPX protease.  
4. Modified Gelatin Sepharose Chromatography and Size Exclusion Purification 










Materials and methods 
Materials 
 
Chemicals and reagents 
Name Producer (company) 
Ammonium sulphate, Magnesium sulphate, bovine 
serum albumin (BSA), Magnesium chloride (MgCl2), 
Sodium acetate, Glacial acetic acid, SDS, Glycerol, 
Bromophenol blue, Gelatin bloom 300, TEMED, 
Glycine, Acetic acid (HAc), Methanol, Sodium chloride 
(NaCl), Brij-35, EDTA, Pefabloc, DTT, E64, HEPES, 
Streptomycin (10 mg streptomycin per ml in 0,9% NaCl), 
Trypan Blue, Tween 20 
Sigma-Aldrich Chemical 
Co. 
TRIS hydrochloride (TRIS-HCl), DMSO, Coomassie 




EDTA BDH (Poole, UK) 
Agarose Cambrex Bio-sciences, 
Denmark 
Dpn I restriction enzyme (10 U/µl) Invitrogen 
NuPAGE-4-12%, Bis-Tris Gel 1.0 mm x 12 well SDS-
PAGE gel 
PfuUltra High- Fidelity DNA polymerase (2.5 U/µl) Agilent Technologies 
Western Blotting Luminol Reagent Santa Cruz 
Biotechnology Inc. 
GelRedTM Nucleic Acid Gel Stain Biotium 
Biotinylated Protein Ladder Detection Pack Cell Signaling 
Technology, Inc 
Kanamycin Thermo Scientific 
(Rockford, IL, USA) SeeBlue®Pre-stained Standard 
Spectra™ Multicolor High Range Protein Ladder 
Fetal Bovine Serum Biochrom AG, 
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XL1-Blue supercompetent cells Agilent Technologies 
P-250 kDa protein Ladder  New England Biolabs 
 1 kb DNA ladder (Cat. No. N3232S) 
Agarose, Low melt preparative Grade BIO-RAD 




Name  Producer (Company) Cat. No. 
QuikChange II XL Site-
Directed Mutagenesis Kit 









QIAprep Spin Miniprep Kit QIAGEN® 27106 
BigDye® Terminator v3.1 
Cycle Sequencing Kit 
Applied Biosystems 4337456 
 
Buffers and solutions used for the different methods 
TRIS-HCL 
1 M Tris-HCl, pH 8.0   
 
To make 1 Liter: 
121.1 g Tris-base (MW: 121.14) dissolved in  
Milli-Q water pH adjusted to 8.0 with HCl 
Volume adjusted to 1 L with Milli-Q water 
Preparation of Primer stock 
TE buffer 10 mM Tris-HCl, pH 8.0 
0.1 mM EDTA 
QuikChange II Site- Directed Mutagenesis 
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10x reaction buffer 100 mM KCl 
100 mM (NH4)2SO4, 
200 mM Tris-HCl, pH 8.8 
20 mM MgSO4 
1% Triton®X-100  
1 mg/ml nuclease-free bovine serum albumin 
(BSA) 
Plasmid purification (Qiagen Kit Buffers) 
Buffer P1 50 mM Tris-HCl pH 8.0 
10 mM EDTA 
100 μg/ml RNaseA 
Buffer P2      
 
200 mM NaOH 
1% SDS 
Buffer N3 4.2 M Gu-HCl 
0.9 M potassium acetate 
pH 4.8 
Buffer PB 5 M Gu-HCl 
30% isopropanol 
Buffer PE 10 mM Tris-HCl pH 7.5 
80% ethanol 
Buffer EB 10 mM Tris-Cl, pH 8.5 
DNA sequencing 
5x sequencing buffer  
 
400 mM Tris-HCl, pH 9.0 
10 mM MgCl2 
Agarose gel electrophoresis 
50x TAE (Tris (2 M)-Acetate (1 
M)-EDTA (50 mM) buffer stock 
solution (working solution 1x) 
 
To make 1 liter of 50x TAE: 
242 g Tris-base disolved in 700 ml H2O  
57.1 mL glacial acetic acid 
100 ml of 500 mM EDTA (pH 8.0) solution 
Add H2O to 1 liter 
1% agarose 
 
To make 100 ml:  
1 g agarose 
100 ml 1x TAE buffer 
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5x loading buffer 
0.25 M Tris-HCl pH 6.8 
10% SDS 
50% glycerol 
0.5% Bromophenol blue 
Gelatin Zymography 
Gelatin (2%)  
 
To make 10 ml: 
0.2 g Gelatin bloom 300  
10 ml Milli-Q water  
Concentrating gel buffer  
 
0.5 M Tris-HCl, pH 6.8  
0.4% SDS 
Separating gel buffer  1.5 M Tris-HCl, pH 8.8 
 0.4% SDS 
Separating gel (7.5% 
acrylamide) 
 
To make 4.507 ml: 
1.120 ml Separating gel buffer  
0.225 ml of 2% gelatin  
2.266 ml Milli-Q Water 
0. 874 ml of 40% Acrylamide 
7 µl TEMED 
15 µl 10% Ammonium persulfate   
Stacking gel (4% acrylamide) 
 
To make 1.498 ml: 
0.186 ml Stacking gel buffer  
1.145 ml Milli-Q water   
0.155 ml 40% Acrylamide 
4 µl TEMED  
8 µl of 10% ammonium persulfate   
Electrophoresis Buffer, pH 8.3 
(10X)  
 
To make 1 Liter: 
30 g Tris-HCl  
144 g Glycine  
10 g SDS (final conc. 1%) 
1 litre Milli-Q water 
pH adjusted to 8.3 with conc. HCl 
Staining solution stock  To make 200 ml: 
0.4 g Coomassie Brilliant Blue  
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120 ml Methanol   
80 ml Milli-Q water   
Staining solution  
 
 
20 ml Staining solution stock 
20 ml of 20% acetic acid  
Staining stock solution is first filtered and was 
mixed with 20% acetic acid. 
Washing buffer  
 
To make 400 ml: 
10 ml Triton X-100 (warm)  
390 ml Milli-Q water 
De-staining solution 
 
To make 400 ml: 
120 ml Methanol  
40 ml of 100% Acetic acid   
240 ml Milli-Q water 
Developing or incubation buffer 
10x  
 
To make 1 liter:  
12.1 g Tris-base (MW:121.14 g/mol)  
63.0 g Tris-HCL(MW:157.60 g/mol)   
117 g NaCl (MW:58.44 g/mol) 
7.4 g CaCl2-2H2O (MW: 147.02 g/mol) 
6.7 g 30% Brij-35  
Milli-Q water added to give the total volume of 1 
liter. pH 7.8 
EDTA (10 mM) 
 
1 ml of 0.5 M EDTA in 50 ml washing buffer.  
500 μl of 0.5 M EDTA in 25 ml Incubation buffer  
Pefabloc (1 mM)  
 
100 μl of 0.5 M pefabloc in 50 ml washing buffer 
50 μl of 0.5 M pefabloc in 25 ml incubation buffer 
E64 (10 μM) (3.2 mM E64 in 
DMSO) 
156 μl of 3.2 mM E64 in 500 ml washing buffer 
78 μl of 3.2 mM E64 in 25 ml incubation buffer 
0.5 M DTT  80 µl 5x Sample buffer 
20 µl 2.5 M DTT  
Gelatin Sepharose Chromatography assay 
Equilibrium or binding buffer To make 500 ml: 
11.9 g HEPES (MW:238.30) pH 7.5 
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0.186 g CaCl2 (MW:74.56)  
Milli-Q water added to give the total volume 500 
ml 
PH adjusted with NaOH 
Washing buffer To make 100 ml: 
2.38 g HEPES (MW:238.30) pH 7.5 
0.0372 g CaCl2 (MW: 74.56) 
5.8 g NaCl (MW: 58.44)  
Milli-Q water added to give the total volume 100 
ml. 
 pH adjusted with NaOH 
Elution buffer  To make 10 ml: 
 9.25 ml equilibrium buffer,  
0.75 ml DMSO (100%) 
pH 7.5 
Western blotting 
1xTBST  To make 1 Liter: 
30 ml 5 M NaCl 
20 ml 1 M Tris, pH 8.0 1 ml Tween 20  
Volume adjusted to 1 L with Milli-Q water 
Blocking buffer 
 
To make 150 ml: 
 7. 5 g 5% Non-fat milk powder   
150 ml 1x TBST   
1xNuPAGE Running Buffer 
(MES-SDS) 
 
To make 600 ml: 
30 ml MES-SDS running buffer (20x)   
570 ml Milli-Q water  
Blotting buffer  To make 1 liter: 
5.8 g Tris-base (MW: 121.14)   
29 g Glycine (MW: 75.07)   
800 ml Milli-Q water   











Sequences (5′-3′) Manufacturer 

















M-13 (-20) Forward 
primer 
GTAAAACGACGGCCAG 
M-13 (-24) Reverse 
primer 
 AACAGCTATGACCATG 
Forward primer for 
sequencing mid-
part of MMP-9 
GCGTCGTGGTTCCAACTCGGTTTGGAA 
ACG   
 
Antibiotic Working Concentration 
(μg/ml) 
Method 
Streptomycin/Penicilin 50 μg/ml/50 IU/ml Sf9 cell culture 
Kanamycin 50 μg/ml Bacterial culture 
Antigen Antibody description (dilutions) Manufacturer, Cat. 
number 
MMP-9 Rabbit Polyclonal anti-MMP-9  
(1: 2500x of 5.1 mg/ml stock) 
Custom made by 




Horseradish Peroxidase (HRP) 
conjugate goat Anti-Rabbit IgG 
(1:2000x of 1 mg/ml) 
Southern Biotech 
(Birmingham, AL, 












V5 Reverse Primer ACCGAGGAGAGGGTTAGGGAT 
 
Insect cells and growth media 




 1x107 cells in 1 ml 60% 
Grace's Media, 30% heat 
inactivated FBS, and 10% 
DMSO 




























(LAH) and yeastolate, and 
supplemented with 10% 
Fetal Bovine Serum (FBS), 
1% glutamin (if media is 











streptomycin (50 μg/ml)  






To make 1 liter:  
10 g Peptone 140,  
5 g Yeast Extract  







SOC 2% tryptone,  
0.5% yeast extract,  
10 mM NaCl  
2.5 mM KCl  
10 mM MgCl2,  
10 mM MgSO4 
















LB Agar plate  
 1 Litre: 15 g agar,1000 ml distilled water, 5 g yeast 
extract, 10 g NaCl, 10 g Bacto-pepton, pH 7.5 
 
 
Instruments and software 
Instrument Description and 
software 
Manufacturer 
LEICA DFC320  Light Microscope Leica Microsystems Inc. 
Lumi-Imager F1TM Blot Analyzer with 
LumiAnalyst software 
Mannheim Boehringer GmBH 
Image Quant LAS 4000 
image reader 
Digital Imaging system 
with the ImageQuant 
LAS 400 software 
General Electric health care Bio-
science AB (Uppsala, Sweden) 
NanoDrop 2000 
Spectrophotometer 
Thermo Software IQ Thermo Fisher Scientific 
Western blot electrophoresis (powerEase 500) for 
SDS-PAGE 
Invitrogen Life Technologies 
(California, USA) 
Software for alignment Bioedit sequence 
alignment editor 7.2 
http://bioedit.software.informer.c
om/7.2 
MEROPS  Peptidase database merops.sanger.ac.uk 
ExPASy  SIB Bioinformatics 
Resource Portal 
https://www.expasy.org/ 
Speed Vac concentrator 
(2211 superrac), 
hydrostatic pump 
 Savant Instruments Inc 





Mutagenesis is a method to change or delete the nucleotides of DNA. Several 
methods can be used to generate mutations into the DNA sequence. Random 
mutagenesis generates a variable amount of unspecific mutations into different sites 
of the DNA sequence (Glick, 2010). In contrast, Site-directed Mutagenesis create a 
specific and targeted mutation in the known DNA. A commercial kit called 
QuikChange® site-directed mutagenesis (Agilent technologies) can be used for 
oligonucleotide-directed or site-directed mutagenesis. In this technique, a point 
mutations can be inserted into DNA which results in a mutation in the amino acid of a 
protein that the gene code for. This technique does not require specialized vectors, 
unique restriction sites or multiple transformations. However, the basic procedure does 
require a dsDNA vector containing the gene of interest and two synthetic 
oligonucleotide primers which contain the desired mutation. Typically, site-directed 
mutagenesis is performed using a PCR-based method. In the PCR, the plasmid is first 
denatured and then the reverse and forward primers are allowed to anneal to their 
complementary nucleotide bases in the template strand. The primers are extended by 
PfuUltra high-fidelity (HF) DNA polymerase and thereby generate a mutated plasmid 
containing staggered nicks. This method uses PfuUltra HF DNA polymerase instead 
of Taq DNA polymerase because pfuUtra high-fidelity (HF) DNA polymerase has 18-
fold higher fidelity in DNA synthesis than Taq DNA polymerase. 
The PCR product is then treated with Dpn I endonuclease which target sequence is 
5´-GATC-3′. It is used to digest the parental DNA template and to select for the newly 
synthesized mutated DNA. After digestion of the methylated template strand, the XL1-
Blue supercompetent bacteria are transformed with the nicked newly synthesized 
mutated DNA. After transformation the supercompetent bacteria repair the nicks in the 







Designing of mutagenic primers 
Primers were designed with 54 bp in length with a melting temperature more than 
78ºC.The desired mutation was almost in the middle of the primers with around 25 
bases of correct sequence on both sides. The GC content was more than 40% and 
both primers terminated with two C’s. Both of the mutagenic primers contained the 
mutated nucleotide. The codon GAA coding for the amino acid glutamate (E) at 
position 448 (E448) of MMP-9 was mutated into the stop codon TAA by replacing the 
G with a T. 
 
 
Figure.14 Overview of the Site-Directed Mutagenesis. PCR is performed to 
generate mutation in the target site. Plasmid is denatured and mutagenic primers 
containing mutation are annealed into the plasmid. Primers are extended by pFuUltra 
DNA polymerase. Daughter strand contain the desired mutation and methylated 
template strands are digested by DpnI restriction enzyme. 
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PCR Primer Stocks preparation 
Before opening the tube containing the lyophilized (freeze-dry) primer, the tube was 
centrifuged for 1 minute at 13.000 rpm in a table top centrifuge to ensure that the 
powder was collected in the bottom of the tube. In order to prepare 100 μM stock 
solution of the mutagenesis primer, the information in the technical datasheet that was 
provided along with primer tube by the company was used. 108 ul of 1x TE buffer was 
added to the pellet and mixed properly by inverting the primers tube gently. The primer 
stock solution was stored at -20ºC. This tube was used further to make working 
solutions when needed. To generate 10 μM working solution of the primers, 10 mM 
Tris, pH 8.8 was used. 
 
Polymerase chain reaction (PCR)  
PCR is a process by which a DNA fragment is amplified many times to yield huge 
number of copies of that particular DNA or gene. In PCR, a pair of synthetic 
oligonucleotides, called primers, are used to initiate DNA synthesis. Furthermore, a 
heat stable DNA polymerase and a reaction buffer containing nucleotides are required. 
A commonly used DNA polymerase is the Taq enzyme, originally isolated from the 
bacterium Thermus aquaticus. This enzyme produces a new DNA strand by 
elongating the strand from the primers by incorporation of deoxyribonucleotides 
triphosphates (dNTPs) in an order based on the template DNA strand. For producing 
sufficient copies of the PCR product, the reaction mixture undergoes a cycle of 
temperature changes. A denaturation step that causes the DNA strands to separate 
or melt at high temperature of 94-98ºC for a few seconds. During an annealing step 
the primers bind to the target sequence in the template. At this step the temperature 
is lowered according to the melting temperature (Tm) of the primers. Normally the 
annealing temperature is around 50-70ºC. An extension step is where the Taq DNA 
polymerase uses the primers as a starting point to create a complimentary strand by 
adding dNTPs to the 5’ end of the primers. These three steps are repeated for 30-40 
cycles. Provided that there are sufficient reagents, at the end of one PCR cycle the 






Donor vector pDONR221- MMP-9 
The vector pDONR221-MMP-9 was provided by Dr. Nabin Malla in our research 
group. In brief, the construct was generated using Gateway®technology (Invitorgen, 
Van Allen Way, USA) where a BP recombination reaction between attB-flanking DNA 
fragment containing the gene encoding human MMP-9 and attP-site in the donor 
vector pDONR221 gave rise to attL-flanked pDONR221-MMP-9. The attB-flanked 
human MMP-9 gene in the pEZ-02-vector was purchased from GeneCopoeia, 





Site directed mutagenesis of MMP-9  
Using the template pDONR221-MMP-9, mutagenesis was performed according to the 
protocol for the QuikChange II site directed mutagenesis kit. The reagents and the 
PCR program used for PCR is shown in table 1 and 2, and the mutagenic primers is 




Figure 15. Generation of the pDONR221-MMP-9 construct using 
Gateway®technology. The gene of interest (MMP-9) is inserted by BP recombination 
reaction between a donor vector pDONR221 and attB flanking MMP-9 DNA. The reaction 
was catalysed by the BP clonase enzyme. 
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Table 1. Setup for the mutagenesis reaction 
 
Reagent Amount (one sample) 
10X reaction buffer 5 μl 
Template pDONR221-MMP-9 (50 ng/µl) 1 μl 
Mutagenic forward primer (125 ng/µl) 1 μl 
Mutagenic reverse primer (125 ng/µl) 1 μl 
dNTP mix (10 mM) 1 μl 
ddH20 40 μl 
PfuUltra HF DNA polymerase (2.5 U/ μl) 1 μl 
Total 50 μl 
 
 
Table 2. PCR programme for the QuikChange II Site-Directed Mutagenesis 
 
Segment Cycle Temperature Time 
1 1 95ºC 30 seconds 
2 12 95ºC 30 seconds 
55ºC 1 minute 
68ºC 7 minutes 
*elongation at 68ºC is estimated to be 1kb/min, thus since pDONR221-MMP-9 is 6.54 kb, the 
time was set to 7 minutes. 
 
Dpn I Digestion of the Amplicon (Amplified product) 
Previously mentioned that Dpn I digest the DNA methylated template and thereby 
reduce the probability of false positive colonies in the transformation. 
 
  The following procedure was conducted: 
1. 2 μl of DpnI restriction enzyme (10 U/μl) was added directly to 50 μl 
amplification reaction.  
2. The mixture was mixed gently and thoroughly by pipetting the solution up and 
down several times then span down in a table top microcentrifuge for 1 minute 
at 12000 rpm.  
51 
 
3. The mixture was then incubated for 1 hour at 37ºC.  
 
Transformation of XL1-Blue supercompetent bacteria  
After digestion of the parental methylated DNA strand, the newly synthesized mutated 
DNA was transformed into XL1-Blue supercompetent bacteria. The bacteria repair the 
nicks in pDONR221-MMP-9ΔH-HPX DNA. As the pDONR221-MMP-9ΔH-HPX 
plasmid contain a kanamycin resistant gene that code for a protein and therefore, only 
XL1-Blue supercompetent bactria that successfully has taken up the mutated plasmid 
will be kanamycin resistant and survive on LB agar plate containing (50 μg/ml) 
kanamycin. In contrast, those XL1-Blue supercompetent bacteria that has not taken 
up the mutated plasmid pDONR221-MMP-9ΔH-HPX are killed with kanamycin.  
 
The following procedure was conducted for the transformation: 
1.  50 μl of XL1-blue cells were gently thawed on ice.  
2. 2 μl of Dpn I treated DNA was mixed with 50 μl XL1-blue cells and incubated 
for on ice for 30 minutes.  
3. The bacteria were heat-shocking by incubation in a water at 42ºC for 45 
seconds, followed by immediate transfer on ice for 2 minutes.  
4. 500 μl pre-warmed SOC medium (Super Optimal Broth with catabolite 
repression) was added to the transformation reaction and incubated at 37ºC for 
1 hour with shaking at 225-250 rpm.  
5. To be sure to get single colonies, two different volume of transformation mixture 
(300 μl and 100 µl) was plated on agar plate containing kanamycin (50 μg/ml) 
by spreading them out using a sterile glass rod. 
6. The agar plates were incubated for overnight at 37ºC.  
7. The number of single colonies were recorded and the plates were wrapped in 
plastic to avoid drying out and stored at 4ºC until further processing of the 
colonies.   
 
QIAprep Spin Miniprep Kit Protocol  
The cells were harvested and used for plasmid DNA extraction. The concentration of 
the purified plasmid was determined by NanoDrop technique. The purification 
procedure is based on lysis of bacterial cells under alkaline conditions. The lysate is 
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subsequently neutralized and adjusted to high-salt binding in one step, the crude 
lysates and denatured and precipitated cellular components are loaded directly onto 
the TurboFilter membrane. RNA, cellular proteins, and metabolites are all removed by 
filtration through the TurboFilter membrane. This is followed by adsorption of plasmid 
DNA onto silica in the presence of high salt. Endonucleases are efficiently removed 
by a brief washing step with Buffer PB. This step was necessary to remove high 
carbohydrate content and trace nuclease activity.  Salts are efficiently removed by a 
brief washing step with Buffer PE. High-quality plasmid DNA is then eluted from the 
QIAprep column with Buffer EB. The purified DNA is ready for immediate use. 
 
The procedure conducted were as follows: 
1. Eight single colonies from the transformations were picked using a sterile 
pipette tip and each single colony was transferred to 3 ml LB media with 
kanamycin and followed by incubation at 37⁰C overnight. 
2. The 3 ml of overnight bacterial culture was pelleted by centrifugation at 
13,000xg for 1 minute and supernatant was discarded.  
3. Pelleted bacterial cells was re-suspended in 250 μl Resuspension Buffer P1 
(with RNase A) by pipetting up and down.  
4. 250 μl Lysis Buffer P2 was added to the tube and the tube was inverted gently 
4–6 times until the solution becomes viscous and slightly clear. This reaction 
step proceeded for maximum 5 minutes. 
5. 350 μl of Neutralization Buffer N3 was added to the tube and the tube was 
inverted immediately 4–6 times in order to avoid localized precipitation. The 
tubes were centrifuged for 10 min at 12,000 rpm in a table top microcentrifuge 
resulting in a white pellet containing cellular materials. 
6. The supernatant was collected and applied to the QIAprep Spin Column by 
pipetting and centrifuged it for 1 minute and then the flow-through was 
discarded. 
7. 500 µl PB Buffer was added on to the QIAprep Spin Column and centrifuged it 
for 1 minute. The flow-through was discarded.  
8. The QIAprep Spin Column was then washed by adding 750 µl Wash Buffer PE 
and centrifuged for 1 minute at 12000 rpm.  
9. The flow-through was discarded followed by another centrifugation of 1 minute 
to remove residual wash buffer.  
53 
 
10. The column was transferred to a new 1.5 ml micro-centrifuge tube and 50 μl of 
elution buffer EB was the added to the column and centrifuged at 12000 rpm 
for 1 minute. 
 
Determining the purified pDONR-MMP-9ΔH-HPX DNA concentration 
and yield 
The purified plasmid DNA was determined by using NanoDrop spectrophotometer at 
A260nm. NanoDrop technology is based on absorbance measurements of the molecules 
to be measured. The molecules like Nucleotides, dsDNA, ssDNA, RNA all absorb light 
at a specific wavelength. Nucleic acids have a peak absorbance of UV light at 260 nm 
where proteins and phenolic compounds have a strong absorbance at 280 nm. 
Several organic compounds have strong absorbance at around 225 nm. Chaotropic 
salts, TRIzol, phenol, and peptide bonds in proteins absorb light between 200 and 230 
nm. 
 
For DNA, absorbance readings are performed at 260 nm where DNA absorbs light 
maximally. The NanoDrop spectrophotometer calculates concentrations and records 
them as ng/μl. DNA concentration can be estimated based on the following equation  
            1OD260 unit = 50 μg/ml (A260 of 1.0 = 50 µg/ml pure dsDNA). 
Concentration (µg/ml) = the absorbance at 260nm × dilution factor × 50 µg/ml 
                  DNA yield (µg) = DNA concentration × total sample volume (ml) 
 
However, other molecules can absorb UV light at 260 nm. RNA also has an absorption 
maximum at 260 nm. The aromatic amino acids present in protein absorb at 280 nm, 
if those are present in the DNA solution, will contribute to the total measurement at 
260 nm. In addition, the presence of guanidine results in higher 260 nm absorbance. 
Therefore, evaluation of DNA purity is necessary. The most common purity calculation 
is the ratio of the absorbance at 260 nm divided by the absorbance at 280 nm. For 
pure DNA and RNA, A260/280 ratios should be somewhere around 1.8, and 2.1 
respectively. A lower ratio indicates the sample is contaminated with protein. On the 
other hand, the A260/230 ratio is used as a secondary measure of nucleic acid purity. 
The A260/230 ratio are commonly expected to be in the range 2.0-2.2. The value 
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1. First, the upper and lower optical surfaces were cleaned with deionized water 
and wiped off both surfaces with laboratory dry wiper.  
2. The software was opened and nucleic acid module was selected.  
3. A blank measurement was performed by pipetting 1 µl elution buffer on the 
lower optic surface.  
4. After the measurement of the blank appeared zero, the optical surfaces were 
wiped off.   
5. 1 µl of undiluted purified plasmid DNA was pipetted on the lower optical 
surface. 
6. The DNA concentration was determined by NanoDrop spectrophotometer 
automatically. 
 
PCR-based DNA sequencing  
DNA sequencing is a process of reading the precise order of nucleotides in a DNA 
molecule. There are two principle methods of determining the sequences, Maxam-
Gilbert chemical method and the Sanger's method, which is also referred to as dideoxy 
sequencing or chain termination method.  Sanger’s method, is based on the use of 
labelled dideoxynucleotides (ddNTP’s) in addition to the normal nucleotides (NTP’s) 
found in DNA. Fluorescently distinguished fluorophores are covalently attached to 
each of four ddNTP`s. The PCR based DNA sequencing is an automated sequencing 
system based on the principle of Sanger's method. Dideoxynucleotides are basically 
the same as nucleotides except them contain a hydrogen group on the 3’ carbon of 
the pentose instead of a hydroxyl group (OH). These modified nucleotides, when 
integrated into a sequence, prevent the addition of further nucleotides. These 
molecules terminate DNA chain elongation because they cannot form a 





For performing the sequencing reaction, a single strand template, single primer 
(forward or reverse complimentary to the template strand), a mixture of a particular 
ddNTPs each labelled with Fluorescent dye, normal dNTP, and a thermostable DNA 
polymerase are required. When the mixture is heated, the two complimentary strands 
in the DNA molecule separates. Then the temperature is lowered so that the primer 
finds its complimentary sequence in the template DNA, and then allowing the 
polymerase to add nucleotides to extend the primer using the single stranded DNA as 
template. The DNA polymerase makes no distinction in adding dNTP or labelled 
ddNTPs, once a ddNTP is incorporated, the synthesis stops. The strand can be 
terminated at any position and resulting in a collection of labelled single stranded DNA 
differing with one nucleotide in length. A laser within an automated DNA sequencing 
machine is used to analyze the DNA strands produced. The results are depicted in the 
form of a chromatogram which is a diagram of colored peaks representing each 
nucleotide for each location in the sequence. A successful sequencing reaction 
depends significantly on DNA purity, sequencing buffer concentration, amount of 
template and the DNA polymerase used.  
 
The following procedure was conducted to sequence purified pDONR221-MMP-
9ΔH-HPX plasmid: 
1. According to protocol 3 µl of 5x BigDye sequencing buffer was taken in total 
volume of 20 µl reaction mix.  
2. The amount of template 270 ng was used as recommended in the protocol.  
3. Three different primers used for the full sequencing of pDONR221-MMP-9ΔH-
HPX.  
4. M-13 forward primer to anneal the M-13 priming site of pDONR221. 
5.  Second forward primer for the sequence of middle part of mutated MMP-9ΔH-
HPX in forward direction. 
6. M-13 reverse primer sequence from the end of MMP-9ΔH-HPX in reverse 
direction. 
7. The sequencing reaction mixture for each reaction was added into the PCR 
tubes on ice and run by the program. 
 
The reagents and PCR program used for sequencing is shown in table 3 and 4. After 
the PCR was done, the tubes were sent to the DNA sequencing core facility of Arctic 
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University hospital northern Norway to resolve the actual sequencing by genetic 
analyzer.   
 
Table 3. Setup for pDONR221-MMP-9ΔH-HPX plasmid sequencing 
Program Reagent Volume (one reaction) 
PCR 5x BigDye sequencing 
buffer 
3 μl 
Template (540 ng/µl) 0.5 μl 




dH20 15.5 μl 
Total 20 µl 
 
Table 4. PCR program for sequencing the pDONR221-MMP-9ΔH-HPX  
Step Number of cycle Temperature Duration 
1 1 96ºC 5 minutes 
2 25 96ºC 10 seconds 
50ºC 5 seconds 
60ºC 4 minutes 
3 1 4ºC ∞ 
 
 
BaculoDirect™Baculovirus Expression System  
By using BaculoDirect™Baculovirus Expression System (Invitrogen, cat.no.12562-
054), any gene of interest can be transferred directly into the Baculovirus genome in 
vitro without the need for extra cloning or recombination in bacteria or insect cells. The 
resulting recombinant Baculovirus DNA is then directly transfected into insect cells for 
generating recombinant virus and to screen for expression. In this system, attR1 and 
attR2 sites in the BaculoDirect™ linear DNA serves as the recombination cloning sites 
for the gene of interest from a Gateway entry clone. In order to generate recombinant 
Baculovirus DNA, LR reaction is performed using LR Clonase®II. Gateway LR 
Clonase enzyme mix promotes in vitro recombination between attL of an entry clone 
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and attR-containing BaculoDirect™Linear DNA (destination vector) to create an attB 
containing expression virus. The actual crossover occurs between homologous 15 bp 
core regions on the two sites but surrounding sequences are also needed as they 
contain the binding sites for the recombination protein (Landy, 1989). The LR reaction 
result in a recombinant Baculovirus DNA containing the gene of interest. 
 
The procedure of LR Recombination Reaction was as follows: 
1. 10 µl (30 ng/µl) Baculovirus linear DNA was mixed with pDONR221-proMMP-9 
(100 ng/µl) (positive control for protein production) in a tube 
2. 10 µl (30 ng/µl) Baculovirus linear DNA was also added to another tube 
containing sample or entry clone pDONR221-MMP-9ΔH-HPX (541.7 ng/µl). 
3. 1x TE buffer was added to the both tubes to give the final volume of 16 µl.  
4. 4 µl LR Clonase® II Enzyme Mix was added to the both positive control tube 
and sample tube. These were mixed well by tapping the tubes several times 
and incubated for 18 hrs at room temperature.  
 
As a control, LR recombination reaction product was amplified in PCR. To do this 1 µl 
aliquot of LR reaction was used as template. The reagents and PCR program used for 
the DNA amplification are summarized in the table 5 and 6. 
 
Table 5. The setup for the PCR of LR reaction product 
Program Reagent Volume (one reaction) 
PCR dH20 15.5 μl 
Polyhedron forward 
primer (10 µM) 
1.5 μl 
V5 reverse Primer (10 
µM) 
1.5 μl 
Template (LR reaction) 1 μl 
10x reaction buffer 5 μl 
dNTP mix (10 mM) 0.5 µl 
Taq DNA polymerase 0.5 µl 




Table 6. The programme used for the PCR for the LR reaction product 
 
The amplified LR product was analysed by performing agarose gel electrophoresis. 
 
Agarose Gel electrophoresis 
Gel electrophoresis is a method for separating and analysing the macromolecules 
DNA or RNA and their fragments based on their size or and charge. Nucleic acids are 
separated by applying an electric field to move the negatively charged molecules 
through an agarose matrix towards the positive pole. The shorter molecules move 
faster and migrate further than longer ones because shorter molecules migrate more 
easily through the pores of the gel.  
 
The following procedure was conducted: 
1. A 1% agarose gel was prepared by weighing out 0.5 g of agarose into a 250 
mL conical flask.  
2. 50 mL of 1x TAE buffer was added to the agarose and swirled to mix properly. 
3.  The mixture was then microwaved for about 1 minute to dissolve the agarose.  
4. The gel was poured slowly into the gel tank. The bubbles if any was removed 
using a disposable tip.  
5. The comb was inserted into the gel and the gel was left for 1 hour to become 
solid.  
6. The comb was carefully removed from the gel and the gel was submerged into 
the gel tank with 1x TAE buffer.  
7. 2 μl of PCR amplified LR recombination reaction product was loaded into one 
well and a molecular standard 1 kb ladder (NEB cat.no N3232S) was also 
loaded in another well.  
8. The electrode position was checked before running the gel. 
Step Number of cycle Temperature Duration 
1 1 95ºC 5 minutes 
2 25 94ºC 45 seconds 
52ºC 1 minute 
72ºC 1.5 minutes 
3 1 72ºC 10 minutes 
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9. The gel was run at 90 V for 1 hr or until the dye of sample buffer is approximately 
75-80% of the way down the gel. 
10. The gel was then stained with GelRed staining solution. 
 
Staining with GelRed 
GelRed™ is a sensitive, stable, environmentally safe fluorescent nucleic acid dye. It 
is designed to replace the highly toxic ethidium bromide for staining dsDNA, ssDNA or 
RNA in agarose or polyacrylamide gels. 
 
The procedure conducted was as follows: 
1. 3x GelRed staining solution was prepared by adding 12 µl of GelRed™10,000x 
stock solution to 40 ml water for a single gel. 
2. 1.6 ml of 2.5 M NaCl was added to the 40 ml GelRed solution to enhance the 
staining sensitivity.  
3. The gel was placed in a suitable polypropylene staining container and the gel 
was submerged by sufficient amount of 3x GelRed staining solution.  
4. The tray was placed in a shaker to agitate the gel gently at room temperature 
for 30 minutes. 
5.  Destaining was performed by placing the gel into a plastic dish and washed 
with water at shaking condition.  
6. The gel was photographed by Image Quant LAS 4000 image reader. 
 
Sf9 insect cells culture 
The Sf9 (Spodoptera frugiperda) insect cells was provided with the BaculoDirectTM 
Transfection and Expression kits (Invitrogen, B825-01). Before performing the 
transfection procedure, we needed Sf9 cells ready to be transfected. Normally, this 
cell line was cultured in two separate manners for two purposes: 
1. Purpose of Suspension cultures: Suspension culture was maintained to 
continue the passaging of the Sf9 cell line in insect growth medium. Viable cells are 
determined before each culture. For generating the sub-culture of Sf9 cells in 
suspension, approximately 2x106 to 4x106 cells/ml were used in suspension with 
supplemented Grace’s Insect growth medium. The seeding densities for the cultures 
throughout the experiment allowed for 3-4 days’ subculture schedule and a cell viability 
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of 90% was observed by trypan blue technique. Sf9 cells were maintained in a non-
humid incubator at 26-28ºC for its most optimal growth. 
 
2. Purpose of Adherent culture: Adherent cells were required for the periodic 
passaging and adherent condition of the cells were required for the transfection 
procedure. When cells were observed to have 90% confluent (a monolayer culture), 
transfection procedure was conducted. 
 
Viable Cells counts using Trypan Blue 
Trypan blue is a dye that can only penetrate the plasma membrane of dead cells. 
Hence, only dead cells appear blue under light microscopy. Counting both viable and 
non-viable cell, the viability of the cell culture can be calculated.  
 
The procedure of staining was as follows: 
1. The Sf9 cells were diluted in complete medium without serum to an 
approximate concentration of 1x 105 to 2x 105.  
2. 10 µl of that cell suspension was placed in a screw cap test tube and 10 µl of 
0.4% Trypan Blue stain was added to the tube. These was mixed thoroughly 
and left for 7 minutes for staining the non-viable cells.  
3. With a cover-slip in place, 10 µl of Trypan Blue suspension mixture was 
transferred to the chambers of hemocytometer for cell counting.  
4. Under microscope, non-viable cells were observed to be stained and viable 
cells excluded the stain. 
5. The blue and non-blue cells within 4 separate squares with triple lines were 
counted and recorded. 






Each square of the hemocytometer represents a total volume of 0.1mm3 or 10-4 cm3. 
Since 1 cm3 is equivalent to approximately 1 ml, the subsequent cell concentration per 
ml is 104. Therefore, cells per square were determined by following the equation: 
 
Cells/ml = the average count per square x dilution factor x 104  
Total cell = cells per ml x the original volume of mixture from which cell sample 
was removed. 
Cell viability = total viable cells (unstained) / total cells (stained and unstained) 
x 100 
 
Transfection of Sf9 cells 
DNA transfer into a new cell is called transfection. Cellfectin®II Reagent is used in 
BaculoDirectTM Expression system for transfection of Sf9 insect cells, it is called lipid-
mediated transfection. Once virus particles enter into the insect cells, they prepare the 
infected cells for viral replication. Actual viral synthesis occurs 0.5 to 6 hours after 
infection following either a lysogenic phase or a lytic phase. In the lysogenic phase, 
the virions enter the nucleus of Sf9 cells, and within 6 hours of infection early-phase 
 
Figure 16. Cell counting system in Hemocytometer. Cells lying within squares and 
touching the upper and left-hand centre lines are counted. The cells touching the bottom 
lines and right hand lines are not counted 
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proteins are produced. In a lytic phase many new phage of viral DNA within the Sf9 
cell are produced and when the number of phage increases within Sf9 cells it damages 
the cells and exits, and subsequently infects other Sf9 cells. Within 20 to 36 hours 
after infection, recombinant gene product is evident. In a recombinant Baculovirus, 
polyhedrin gene is replaced with MMP-9ΔH-HPX gene. During the very late phase of 
infection, the inserted heterologous MMP-9ΔH-HPX gene is placed under the 
transcriptional control of AcNPV polyhedrin promotor. Thus the way, instead of 
polyhedrin protein, recombinant protein is produced.  
  
The procedure of transfection was as follows: 
1. Around 8x 105 Sf9 cells were plated in the 6-well plate allowing cells attach 
for 15 minutes at room temperature in the hood.  
2. Two transfection mixture (A and B) were prepared for both the sample (MMP-
9ΔH-HPX) and positive control (proMMP-9).  
3. Transfection mixture A contained Cellfectin®II reagent and un-supplemented 
Grace’s Insect Medium whereas transfection mixture B contained LR 
recombination reaction and un-supplemented Grace’s Insect Medium.  
4. The transfection mixture A and B were mixed together for positive control 
(proMMP-9). 
5. The mixture A and B for the sample (MMP-9ΔH-HPX) was also mixed 
together and were incubated at room temperature for 25-35 minutes. 
6. The transfection mix from 1 and 2 were added drop wise onto the adherent 
Sf9 cells and incubated for 4 hrs at 27ºC. 
7. The transfection mixture was removed from the well after incubation and 
replaced with 1.8 ml complete growth medium containing 100 µM ganciclovir 
which inhibit the replication of non-recombinant virus within Sf9 cells (Kovacs 
et al., 1991). 
8. The plates were then sealed with a plastic bag and incubated for 72 hours at 
27ºC. 
9. 2 ml of grace’s insect medium from both positive control well and sample well 
were collected in a sterile 15 ml tubes. 
10. The tubes were centrifuged at 3,000 rpm for 5 minutes in order to remove 
cells and large debris.  
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11. The supernatant of both positive control and sample were then transferred to 
fresh 15 ml tubes and stored at -20ºC until further use. These samples are 
referred to as the P1 viral stocks. 
12. 1 ml from P1 viral stock was used for further transfect the fresh Sf9 cells and 
to continue the passages of viral stock P2, P3, P4.  
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel electrophoresis is used for analysing the mixture of proteins based on their 
physical properties such as charge or molecular mass. When polyacrylamide gel 
contains anionic detergent sodium dodecyl sulfate (SDS), it is called SDS-PAGE. 
Normally amino acids that make up proteins might be positive, negative, neutral, or 
polar in nature. Therefore, the overall charge of a protein depends on the sum of the 
charges on the individual amino acid side chains. The SDS-PAGE technique where 
proteins are coated by SDS in a proportion to its total molecular mass and give rise to 
rod-like overall negatively charged complexes. When an electric field is applied, the 
negatively charged complexes are separated based on the differences of their 
molecular masses. Two different gel ‘Stacking’ and ‘Separating’ are used in SDS-
PAGE. The pH of those two gels and buffer is very important for the proteins mobility. 
During electrophoresis, the protein-SDS complexes are concentrated into a narrow 
zone in the stacking gel (pH 6.8) and only effective separation occurs when the 
complex reaches the separating gel (pH 8.8). The pH prevailing in the separating gel 
allow the protein-SDS complexes to move in a uniformed buffered (pH 8.3) electric 
field to separate from each other according to their size and charge (Walker, 1984). 
When an electric field is applied, the uniform negatively charged protein travel from 
concentrating gel through the polyacrylamide matrix based on their molecular size. 
The larger protein molecule travel slower through the polyacrylamide matrix than the 
smaller one. 
 
This technique can be carried out under reducing condition in the presence of a 
reducing agent DTT, or without reducing agent. Reducing agent DTT breaks off 
disulfide bonds of already denatured protein by SDS, which only disrupts the non-
covalent bond between amino acids. Removing the last traces of tertiary and 
quaternary structure of protein by DTT, protein appears as an unfolded simple primary 
64 
 
structure. Hence, the unfolded protein complex under reducing condition travel more 
slowly in the gel than unfolded compact protein complex under non-reducing 
conditions. Comparing reduced and non-reduced samples, molecular size of a protein 
subunit and the information about monomeric or oligomeric forms of protein can be 
obtained. In the current experiments we performed SDS-PAGE both under reduced 
and non-reduced conditions. 
 
The procedure was as follows: 
1.  20 µl protein sample were mixed with 6 µl 5x sample buffer (0.5 M DTT or 
without DTT) and boiled for 4 minutes. 
2.  The sample tubes were centrifuged for 30 seconds at 12000 rpm and then 
loaded in 4-12% NuPAGE ready-made gel along with P-250 kDa protein 
ladder.  
3. 600 ml MES-SDS running buffer was added to the electrophoresis try.  
4. 200V was set for electrophoresis for 35 minutes. 
5.  The gel was removed from the plastic cover and was shake for 5 minutes 
putting in a shaker. This step was repeated twice for 10 minutes.  
6. The gel was stained with 20 ml imperial Coomassie protein staining solution in 
a warming condition in the micro-oven until any band was visible.  
7. De-staining step was accomplished with water and the gel was imaged by 
Quant LAS 4000 image reader. 
 
Gelatin zymography  
Gelatin zymography, an electrophoretic technique where gelatin has been 
incorporated in the gel in order to detect the enzymatic activity of a gelatin degrading 
protease. This technique is commonly based on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). In order to perform gelatin 
zymography, two different types of gel are required; the stacking or concentrating gel 
and the separating gel. The separating gel contains a higher concentration of 
polymerized and cross-linked acrylamide compared to that of the concentrating gel. 
This along with the different pH in the two gel compartments allows for the separation 
of proteins. Concentrating gel concentrate protein in narrow bands. Gelatin 
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zymography is always performed under non-reducing conditions in order to avoid 
inactivation of the enzymes.  
 
When SDS is removed from the protein in washing step, protein refolds. During the 
refolding, the pro-domain (for eg. MMP-9) refolds back to the catalytic domain. Instead 
of refolding back to the correct position, it binds to the catalytic site as a substrate.  
Hence, the pro-domain is cleaved off leading to auto-activation of the MMP. Gelatin 
Zymography, a precise and very sensitive tool to detect gelatin degrading enzymes 
like MMP-9.  
 
Enzyme degradation of the gelatin substrate appears as transparent bands against a 
deep blue background after staining the gel with Coomassie Blue. Using gelatin 
zymography, semi-quantitative measurement of the amount of a protein in a sample 
can be determined. In addition, the molecular weight of the protein and discrimination 
between latent and active species can be identified (Dwek et al., 2012; Snoek-van 
Beurden and Von den Hoff, 2005). The major limitation of this technique is that the net 
proteolytic activity of gelatinases is not obtained as TIMP that inhibits the activity of 
the enzyme is dissociated from the enzyme during SDS-electrophoresis. Moreover, 
the refolding of MMPs after electrophoresis recovers only the part of its original activity.  
 
The following procedure was conducted: 
1.  Zymography apparatus including glass plates was cleaned with 96% ethanol. 
2. A 7.5% separating gel mix were prepared using the reagent were shown in the 
table 2.1.3 and 0.1% gelatin was incorporated into the separating gel allowing 
for the detection of MMP-9 through its degradative capacity.  
3. 7.5% separating gel mix was pipetted between the glass plates avoiding 
bubbles.  
4. The plates were filled about 80% way up leaving space for the stacking gel and 
comb.  
5. A small amount of distilled water was overlaid on top of separating gel to 
achieve a completely flat interface between separating gel and stacking gel. 
The separating gel was allowed to polymerize for about 10 minutes. 




7. The excess water was poured off from polymerized separating gel. 
8. The stacking gel mix was poured avoiding bubbles and comb was inserted.  
9. The comb was removed carefully after the stacking gel was polymerized. 
10. The gel was assembled onto the electrode section of the gel apparatus. 
11.  Central well of the gasket was filled with 1x running buffer and the bottom of 
the tank with 1x running buffer. 
12. Samples were pipetted into wells by using gel loading tips.  
13. 150V and 18 mA was set and the gel was run for 2 hours at 4ºC until the dye 
front reaches the end of the gel. 
14. The apparatus was disassembled and gel was gently placed into a plastic dish 
and washed two times for 15 min in approximately 100 ml 2.5% Triton-X-100 
in order to remove SDS from the gel.  
15. The gel was incubated with 50 ml incubation buffer at 37ºC overnight.  
16. The next day the incubation buffer was discarded and the gel was stained with 
50 ml Coomassie blue staining solution in a shaker for 1 hour. 
17.  The gel was de-stained with de-staining buffer until the background appeared 
as blue due to presence of gelatin and white bands where the gelatin has been 
degraded.  
18. The gel was then photographed by Quant LAS 4000 image reader. 
Protein purification by Gelatin Sepharose Chromatography 
Affinity chromatography technique for protein purification depends on a reversible 
interaction between proteins or group of proteins and a specific ligand which remain 
coupled to a chromatography matrix. This technique is considered to be an ideal 
technique for protein purification with high selectivity and several thousand-fold high 
recovery of active material. In addition, by using this technique a target molecule can 
be separated from complex biological mixtures, native forms can also be separated 
from denatured forms of biological molecules. In order to perform this affinity 
technique, a bio-specific ligand that can be covalently attached to a chromatography 
matrix is necessary. Additionally, the coupled ligand must retain its specific binding 
affinity for the target protein (molecule) and more importantly, the binding between the 
ligand and target molecule must be reversible, allowing the target molecules to 
separate in an active form in the elution step. In our case the technique was referred 
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to as Gelatin Sepharose Affinity Chromatography, where the ligand is gelatin which is 
attached covalently to the Sepharose matrix. The ligand gelatin has affinity to the 
fibronectin type domain of MMP-9. Hence MMP-9 bind to the gelatin reversely and 
MMP-9 can be eluted from the column using a buffer containing 7.5% DMSO. We have 
used this technique to isolate full length proMMP-9 (positive control) and the deletion 
variant of MMP-9 (proMMP-9ΔH-HPX) from the viral stocks (P2-P4).  
 
The following procedure was conducted: 
1. 1 ml column for both sample and positive control were prepared by setting small 
glass wool filter rolls in the bottom of the column. 
2. 200 μl gelatin sepharose was applied on the top of wool filter. The columns 
were then vertically fixed on a stand. 
3.  5 ml washing or binding buffer used 3-4 times in order to wash the column. 
4. 1 ml sample was applied to the column. 
5. 1 ml positive control was applied to another column. 
6. The flow through was collected from the column in 1.5 ml Eppendorf tube. 
7.  500 µl aliquot of the 1.5 ml washing buffer was also collected to verify unbound 
protein material. 
8.  An additional pre-elution step was applied where the buffer contained 0.1% 
DMSO. 
9.  300 µl of elution buffer containing 7.5% DMSO was applied for the final elution.  
10.  Eluted protein was collected in three separate tubes, 100 μl in each.  
 
Concentration of purified proteins and removal of impurities with 
molecular size less than 10 kDa 
In order to concentrate the eluted protein, a spin column with a cut off of 10 kDa 
(Millipore) was used to concentrate the protein molecules that are bigger than 10 kDa.  
 
The procedure was as follows: 
1. 100 μl of proMMP-9 and proMMP-9ΔH-HPX sample were added to the spin 
column and centrifuged at 45000 rpm until it reached 20 μl remaining 
volume. 
2. With 300 µl of 0.1 M HEPES buffer, the samples were centrifuged at 45000 
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rpm. This was repeated 4-5 times in order to remove DMSO from the 
samples. 
3. After centrifugation, the final volume of 20 μl was expected to be DMSO 
free. 
4. The amount of protein in the concentrated samples was determined 
spectrophotometrically by determining the absorption at 280 nm and then 
using Beers law the concentrated proMMP-9ΔH-HPX proteas was then 
determined. 
 
 Beers law     A=ε*c*l                                    
Where A= Absorbance at 280 nm, ε = extinction coefficient (for eg. the extinction 
coefficient of MMP-9 is 114.36 mM-1cm-1 (Murphy and Crabbe, 1995) and MMP-9ΔH-
HPX is 73.06 mM-1cm-1 c = concentration and l = optical path length in cm. Therefore, 
if ε is known, measurement of A gives the concentration directly. The value of l 
depends on the path length of the cuvet. A rapid way to calculate the extinction 
coefficient is by using the ProtPARAM tool from ExPASy with target protein's amino 
acid sequence, which was done for MMP-9ΔH-HPX. In the case of the full length 
proMMP-9, this theoretical calculation (ε=112.73 mM-1cm-1) is close the experimental 
value obtained by Murphy and Crabbe (see above). 
 
Size exclusion purification  
The process of Size Exclusion Chromatography uses a matrix consists of porous 
particles and where molecules separation is achieved according to molecular size and 
shape of the molecules. For separating molecules of different sizes, normally 
molecular sieve properties of different sizes porous matrix are utilized. The SEC matrix 
consist of a range of beads with slightly different pore sizes where the separation 
process depends on the ability of different proteins to enter all, some or none of the 
channels in the porous beads. The length of the column (cm) is a significant parameter 
as it affects the resolution and also time used to elute the sample. In addition, the rate 
of the flow of eluent is another factor to be considered, as it affects the speed at which 
separation of the molecules are obtained. When three different molecules are 
separated using the chromatography where large protein molecules are not able to 
enter into the smaller cavities they pass quickly between the beads and come out of 
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the column in void volume (V0). In contrast, smaller protein molecules enter into the 
cavities and take the longer path around the beads. They come out in what is called 
the elution volume (Ve). Very small particles like potassium dichromate enter also the 
smallest cavities of the beads and these particles are used to define the total volume 
of the column (Vt). In the present investigation a Sephadex G-75 column was used. 
This column can separate proteins with molecular sizes that ranges from 3 to 80 kDa 
and the protein molecule larger than 80 kDa enter in the void volume. 
 
The procedure was as follows: 
1. 6 ml Sephadex G-75 gel was packed in 10 ml pipet.  
2. 2 column volume of equilibrium buffer was used to wash the column. 
3. To get an idea of the separation properties (V0 and Vt) of this column with G-75, 
Blue dextran 2000 (150 µl) and potassium dichromate (100 µl) were used. 
4. The first 2 ml only contained buffer and was discarded. 
5. Blue dextran 2000 came in void volume (V0) and was determined to 2.5-4 ml. 
Potassium dichromate was collected in the total volume (Vt) and was determined 
to 4-5 ml. 
6. Based on the idea above, 100 μl concentrated protease sample was added to 
the Sephadex G-75 column and 16 fractions of 500 µl was collected. 
7. 100 μl gelatin sepharose was added to each 500 μl protease sample and left 
them for 10 minutes.  
1. The gelatin sepharose beads was then washed with washing buffer. 
2. Purified protease was eluted with 100 μl of elution buffer containing 7.5% DMSO. 
 
Mass spectrometry 
Mass spectrometry is an analytical chemistry tool that measures the molecular masses 
of individual compound, chemicals, or atoms precisely by converting them into gas-
phase to ionic species. There are three main section in any mass spectrometer; 
ionization source, the mass analyser and the detector. During ionization event of 
spectrometer, by electron impact that leads to break down the covalent bonds in the 
target molecules leading to generation of high amount of characteristics fragment ions. 
These ions are then accelerated, so all the ions are of same kinetic energy. The 
charged ions are separated and sorted out on the basis of their mass-to-charge ratio. 
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This is done with the help of mass analysers. The detection of the beam of those ions 
while passing through the machine is detected electrically.  The obtained information 
is stored and analysed depending on the type of investigation from which the data are 
formed (Feng et al., 2008).  
 
Western blot analysis 
Western blot also known as protein immunoblot is an extensively used analytical 
technique to detect specific proteins from a complex mixture of proteins that are 
extracted from tissues or cells, or secreted from cells into culture media. This 
technique involves three major steps; protein separation by size or charge, protein 
transfer to the blotting membrane and finally detection of the protein by using specific 
primary and secondary antibodies to recognize the target protein.  
 
The separation of protein from the mixture is attained according to the length of 
polypeptide (molecular weight) or charge through electrophoresis. The separated 
proteins are transferred to the membrane made of nitrocellulose or positively charged 
nylon Polyvinyl Dene Fluoride, (PVDF) by applying an electrical current that induces 
the proteins to migrate from the gel to the membrane. The transferred protein is 
immobilized on the membrane. Thereafter, the protein has been attached to the 
membrane. The membrane is washed with blocking buffer made from non-fat milk 
powder or BSA. This step is necessary to prevent any unspecific binding of primary 
antibodies to the surface of the membrane. The membrane is then incubated with a 
dilute solution of primary antibody which is specific for the protein of interest. After 
which the membrane is washed with TBST to remove unbound primary antibody. The 
membrane is then incubated with blocking buffer containing a diluted secondary 
antibody usually conjugated with a biotin or a reporter enzyme most commonly Horse 
Reddish Peroxidase (HRP) as probe to recognizes the primary antibody. The 
membrane is washed again to remove unbound secondary antibodies. Luminal 
reagents are then added with HRP conjugated antibodies. The enzyme linked to 
secondary antibody convert the luminal reagents to a fluorescent product by which 
antibodies are detected. The thickness and intensity of the band is proportional to the 




The procedure followed was as follows: 
1. A readymade 4-12% NuPAGE SDS-PAGE gel was washed with milli-Q water 
and the white tape set in the bottom of the gel and comb were taken out 
carefully. 
2.  The gel was rinsed with 1xNuPAGE running buffer and was set in the mini-cell 
rack orienting inward.  
3. In case of one gel, a dam gel was used as gel number two.  
4. The electrophoresis inner camber was filled with 1xNuPAGE running buffer. It 
was necessary to first to check for any buffer leakage. 
5. The outer chamber was filled with 1xNuPAGE running buffer. 10 µl sample 
along with 8 µl multicolor protein marker and 7 µl biotin-labelled molecular 
weight protein standards were loaded into the gel. 
6. The gel was run for 35 minutes at 200V.  
7. PVDF- membrane was cut in the same size of the gel and kept them in 
methanol for 3 seconds followed by 10 seconds in water and then in blotting 
buffer for more than 5 minutes.  
8. The gel was removed from the casket by breaking the sides of the casket using 
a gel – knife and the lowest part of the gel was cut off and discarded. 
9. The pre-wetted PVDF-membrane was placed on the top of gel while the pre-
wetted filters were on the top of PVDF-membrane. 
10.  Air bubbles were removed by rolling a glass rod over the membrane slowly. 
11.  The pre-wetted pads and filter-paper were placed in the cathode core for 
blotting. The inner chamber of cathode core was filled with blotting buffer while 
outer chamber with water for cooling.  
12. Setting the lid in the proper way, the blotting program was run and the 
membrane was washed keeping inside a tube containing 5 ml 1X TBST for 5 
minutes in a rotating wheel.  
13. The membrane was then blocked with 5 ml blocking buffer for an hour and then 
the membrane was incubated with 5 µl 1000x diluted Rabbit anti-MMP-9 
primary antibody overnight at 4ºC. 
14.  The gel was washed with 1x TBST for three time each 5 minutes and followed 
by incubation with HRP conjugated 2.5 µl 2000x diluted goat anti-rabbit IgG 
secondary antibodies for an hour at room temperature. 
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15.  The membrane was washed for three times with 5 ml 1X TBST each five 
minutes.  
16. 1:1 ratio of luminal reagents (A and B) for antibody detection was added to the 
membrane and left for 1 minute.  
























Results and Discussions 
Generating a truncated variant of proMMP-9, the proMMP-
9ΔH-HPX 
Structural and domain analysis has shown that proMMP-9 is composed of several 
domains including a hinge region and hemopexin-like domain. (Figure 17A). In order 
to produce a proMMP-9 that lacks the hinge region and the hemopexin domain, a point 
mutation was introduced at the beginning of the hinge region by site-directed 
mutagenesis using the QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies). The vector pDONR221-MMP-9 containing the full length human 
preproMMP-9 open reading frame (ORF) was provided by Dr. Nabin Malla in our 
research group and used as template in the site-directed mutagenesis reaction. 
 
 
Figure 17. proMMP-9ΔH-HPX truncated variant from the full length proMMP-9. A. 
Domain representation of full length preproMMP-9. Amino acid sequences highlighted 
in blue color (normal) are the end part of catalytic domain and red in color are some 
part of hinge region. The amino acid E448 in the hinge region was mutated by site 
directed mutagenesis is displayed in black color (bold) and it is indicated by a black 
arrowhead. B. The corresponding nucleotide sequences of amino acids (438-455) were 
used for primers design where triplet codon GAA for amino acid E was mutated and it 
is indicated in black (bold). C. The resulting stop codon (TAA) is shown in the sequence 





As site-directed mutagenesis is a PCR based method, we needed a set of two primers; 
forward primer and reverse primer. For introducing the mutation, primers were 
designed with the nucleotide sequences from 438-455 surrounding E448 amino acid 
(Fig.17B). In both primers, G in the GAA codon was replaced by T resulting in a stop 
codon and thereby producing a proMMP-9 of 447 amino acids long lacking the hinge 
region and hemopexin-like domain instead of the wild-type 707 amino acid protein 
(Fig.17D).  
 
Transformation of site directed mutagenesis product into 
XL1-Blue supercompetent bacteria and Sequencing 
After transforming the DpnI treated mutagenesis product (pDONR221-MMP-9ΔH-
HPX) into XL1-Blue supercompetent bacteria, the transformation mix was spread on 
kanamycin plates for selection of only transformed bacteria.  A total of eight (8) 
colonies were picked from the agar plates and then these were allowed to grow in 
suspension. Thereafter, bacterial cells were harvested and by following the procedure 
of QIAprep Spin Miniprep Kit Protocol, we purified the bacterial plasmid. The DNA 
concentration of purified plasmid was then measured by NanoDrop 
Spectrophotometer and after that the plasmid was sequenced by using three different 
primers in order to verify the presence of the mutation. Using the forward primer M13 
(-20), which binds to the priming site of the pDONR221, gave a sequence of 940 
nucleotides of preproMMP-9ΔH-HPX in forward direction without covering the area 
where the desired mutation was inserted. On the other hand, the second forward 
primer designed from the nucleotide sequences that correspond to amino acids G195 
to D205 of preproMMP-9ΔH-HPX covered the sequence of the mutated area and 
showed a correct mutation introducing a stop codon. The M13 reverse primer was 
used to sequence the hemopexin and hinge region of preproMMP-9ΔH-HPX including 
the mutated area (Fig.18). The obtained sequences were also analyzed to ascertain 
that the nucleotide sequences of the entire preproMMP-9ΔH-HPX ORF in the gateway 





The sequence alignment analysis showed that only a single desired mutation was 
produced within the entire preproMMP-9ΔH-HPX ORF. The mutated nucleotide was 
marked in the figure 19 and full sequence of preproMMP-9ΔH-HPX is attached in the 
Appendix (A1). 
Figure 18. Analysis the sequence of preproMMP-9ΔH-HPX. Nucleotide sequence 
representation of proMMPΔH-HPX containing pDONR221 entry clone plasmid showing 
points of anneal of three different primers. A. The M-13 forward primer anneal upstream 
of the gateway attL sequence of the pDONR221-preproMMP-9ΔH-HPX vector and 
sequenced until about 940(1010) nucleotide bases of the MMP-9 DNA. B. Another 
forward primer which sequenced from 696(767) till 1689 (1760) nucleotide bases and C. 
The M-13 reverse primer sequenced in the reverse direction from approximately 2124 
(2195) till 1103(1174) nucleotides of preproMMP-9ΔH-HPX. 
 
 
Figure 19. Sequence alignment of preproMMP-9ΔH-HPX. pDONR221-preproMMP-
9ΔH-HPX was sequenced and the resulting sequence was aligned with wild-type 
proMMP-9. The highlighted box shows the mutation of G to T in the hinge region of 
MMP-9 replacing the codon GAA for glutamate to TAA a stop codon. 
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Generation of a recombinant Baculovirus DNA vector by Gateway LR 
recombination reaction  
In pDONR221-MMP-9ΔH-HPX, the preproMMP-9ΔH-HPX ORF is flanked with attL 
sites. Both pDONR221-MMP-9ΔH-HPX and pDONR221-proMMP-9 encoding normal 
full length proMMP-9, were mixed with linear Baculovirus DNA containing attR site 
according to the protocol of Baculo-Direct Baculovirus expression system. In order to 
transfer the ORFs from the pDONR221-vectors to the Baculovirus DNA, an LR 
recombination reaction was performed. In order to verify the successful insertion within 
the Baculovirus genome, PCR using polyhedrin forward and V5 reverse primer was 
performed with the LR recombination products as template. The amplified DNA was 
then subjected to 1% agarose gel electrophoresis. Analysis of the gel electrophoresis 
result revealed that none of the bands corresponded to the expected 2.4 kb size of the 
preproMMP-9ΔH-HPX ORF inserted into the linear Baculovirus genome (Fig. 20) (See 
appendix A2).  
 
 
Figure 20. Agarose gel electrophoresis of LR recombination reaction 
product. 1% agarose gel showing the product of LR reaction where the 
preproMMP-9ΔH-HPX ORF in the Baculovirus genome was used as a template. 
The first lane is a 1kb DNA ladder and the second lane is the amplified LR 
product. An arrowhead indicates the position where the right size LR product was 
expected to appear.  
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The BaculoDirect™Baculovirus Expression System is a well-established method with 
an apparent 100% yield of recombinant viruses (Kost et al., 2005) and PCR is a 
standard method, still we were unable to obtain a PCR product of the expected size 
and therefore unable to verify correct insertion using this method. The failure might be 
due to unspecific primer binding, too low or high concentration of template or primer, 
or sub-optimal annealing temperature of the primers or sub-optimal primer design.  
 
Upon closer analysis of the polyhedrin and V5 primers provided with the kit, we found 
that the melting temperature (Tm) of the polyhedrin forward primer was theoretically 
estimated to be 50ºC, whereas V5 reverse primer was 66ºC. According to protocol, 
the annealing temperature used for the PCR reaction at 52ºC. For a successful PCR 
product, it is important to have a similar Tm for both primers and ideally it is 
recommended to select an annealing temperature 3 to 5 degrees lower than the Tm 
of the primer so that both forward and reverse primers can bind to the template. In 
other case, going too low with the annealing temperature, the primers might anneal to 
nonspecific sequences leading to undesired multiple PCR products.  
 
In our present investigation, analysis of the agarose gel result revealed at least seven 
bands of different sizes where four smaller bands were strong and three bigger sizes 
were weak bands (Fig. 20). The results indicated that the primers annealed at many 
different places in the template, probably due to a too low annealing temperature 
allowing the V5 primer to anneal un-specifically.  Re-amplification with changing 
annealing temperature was found to be difficult because the difference of melting 
temperature of those two primers were so big.  
 
However, when we observed that the transfection of Sf9 cells with LR product was 
successful in producing our target proteases (proMMP-9ΔH-HPX and proMMP-9), we 







Transfection of Sf9 insect cells with recombinant linear 
Baculovirus DNA  
The Sf9 insect cell from Life Technologies are the traditional cell lines suitable for 
producing recombinant protein using the Baculovirus expression system protocol. 
Throughout the transfection procedure the Sf9 cells culture were always examined in 
order to be sure that cells were regular in shape and 90% confluent (monolayer 
culture). The percentage of cell’s viability was also determined before each 
transfection procedure by staining with trypan blue followed by examination and 
counting using regular phase contrast microscopy. According to the protocol around 
8x105 cell/ml viable Sf9 cells were used for each transfection procedure. 
 
For the transfection, the solutions containing recombinant Baculovirus DNA with the 
preproMMP-9ΔH-HPX and preproMMP-9, respectively, were added drop wise onto 
the Sf9 cells that were cultured in complete Grace’s insect growth medium. The 
transfected cells were then incubated for 72 hours at 27ºC, and thereafter the cells 
were examined under light microscope (Leica DFC320). Floating and disrupted Sf9 
cells indicated the production of recombinant viruses since high production of viral 
particles might lead to cell lysis. When we observed symptom of virus production, the 
insect growth medium was collected and named Passages of viral stock or P1. This 
P1 viral stock was expanded in fresh Sf9 cells to produce P2, P3 and P4 virus stock 
with increasing virus titre. All the (P1-P4) passages of viral stocks were analysed by 
Gelatin Zymography using Sodium Dodecyl Sulfate (SDS)-polyacrylamide gels 
copolymerized with 0.1% gelatin in order to analyse the gelatinolytic activity of the 
protease produced by the infected Sf9 cells.  
 
Since LR recombination reaction was performed for insertion of preproMMP-9 and 
preproMMP-9ΔH-HPX into Baculovirus genome and Sf9 cells were transfected with 
the resulted recombinant Baculovirus genome, it was expected that the Sf9 cells would 
produce proMMP-9 and proMMP-9ΔH-HPX proteins. Additionally, previous results 
from our research group have shown that Sf9 cells do not produce any gelatinases, 




Since our aim was to produce a truncated proMMP-9, therefore, the size of the 
protease was expected to be smaller than the size of the full length proMMP-9. A study 
by Philippe E. Van den Steen, et.al. showed that recombinant proMMP-9 produced by 
Sf9 cells lacking both the hinge and hemopexin domain was around 48 kDa and the 
same molecular weight was observed under both reducing and non-reducing 
conditions (Van den Steen, 2006). In the present study, Gelatin Zymography of all 
Passages of viral stock revealed that gelatin degrading activity by the proteases in 
both the proMMP-9 and the proMMP-9ΔH-HPX sample were so strong that it was 






Figure 21. Gelatin zymography showing the gelatin degrading proteases in the 
passages of viral stock produced in Sf9 cells.  All passages of viral stock were 20x 
diluted. Standards MMP-9/2 in the lane 1 and Trypsin in lane 2. Lane 3-6 shows the 
viral stock (P1-P4) of positive control containing proMMP-9 and lane 7-10 represents 
the viral stocks (P1-P4) of the proMMP-9ΔH-HPX protease sample. Coomassie Blue 
was used for staining the gel. White bands denote proteolytic activity of the proteases 
over the blue background which contain gelatin. Two open arrows indicate two protein 
bands around 85 kDa and 82 kDa in the positive control and closed arrow indicates 




Additionally, the many bands showing gelatinolytic activity in both samples were very 
similar, with only some exceptions. As shown in figure 21, it was found that the P1 
viral stock of the proMMP-9 sample showed doublets bands with molecular size of 
around 82 and 85 kDa, whereas the P1 viral stock in the proMMP-9ΔH-HPX sample 
showed a single strong band of approximately 48 kDa. This could represent the 
proMMP-9ΔH-HPX protease as the estimated size calculated based on data from the 
MEROPS database and ExPASY analysis was 48 kDa. The contamination might be 
occurred from the P2 viral stock of both samples. The unexpected protease bands 
observed in P2 viral stock were also present in the following viral stocks. However, the 





Figure 22. Gelatin degrading proteases in the medium from Sf9 cells. All samples 
were diluted 200x with 0.1M HEPES buffer. Control 1 was insect growth medium 
containing MMP-9ΔHPX protease whereas control 2, 4 and 5 were P1, P2 and P4 viral 
stocks of proMMP-9. In control 3, un-transfected insect growth medium of Sf9 cell. P4 
viral stock from the sample containing MMP-9ΔH-HPX is shown in the lane no 4. Two 
open arrows indicate the molecular sizes of 82 kDa and 85 kDa protease bands in the 
positive control proMMP-9. Another arrow (closed) indicates the expected proMMP-




samples were dilute 200x and analysed by Gelatin Zymography. Several control 
samples were included in order to determine the sizes of the protease bands (Fig. 22). 
Analysing the result of the Gelatin Zymography it was observed that the activity of the 
two contaminating bands at approximate 60 kDa and 120 kDa in control 3, was 
common in other samples as well, including the negative control. Besides these 
common bands, additional bands around 82 kDa and 85 kDa were observed in the P4 
viral stocks of the proMMP-9 sample. Based on the knowledge that proMMP-9 is 
heavily glycosylated, the double bands most likely represent proMMP-9 with different 
degree of glycosylation. In the proMMP-9ΔH-HPX sample in lane 4, a band of the 
expected size of 48 kDa was observed. Thus, from this we concluded that we had 
successfully produced proMMP-9 and proMMP-9ΔH-HPX, although with several 
contaminating proteins. Thus, a purification protocol was needed in order to exclude 
the contaminating proteins and obtain high purify of the samples.  
 
Protein purification by Gelatin Sepharose Chromatography 
Since the three fibronectin-like repeats in the catalytic domain of MMP-9 is known to 
have affinity for gelatin (Goldberg et al., 1992), the technique Gelatin Sepharose 
affinity chromatography was performed to purify the proMMP-9ΔH-HPX and proMMP-
9. The binding between gelatin and the FnII module in MMP-9 is reversible, and the 
two MMP-9 enzymes can be detached from the column by the addition of 7.5% DMSO. 
During purification, along with eluted proteases, aliquots of the flow through and 
washing buffer with 1 M NaCl were collected. NaCl give ionic strength to the 
purification buffer which helps to prevent nonspecific ionic interactions between 
proteins and the column. Hence, aliquots from the washing step were collected to 
observe if the nonspecific protease passed through the column and was removed from 
the sample. All aliquots were subjected to gelatin zymography. The result of the 
zymography (Fig. 23) revealed that the eluted proMMP-9ΔH-HPX protease in lane 3 
contained a strong band around 48 kDa and two weak contaminating bands around 
60 kDa and 120 kDa having gelatinase activity. Eluted proMMP-9 contained bands 
with molecular sizes of around 82 kDa and 85 kDa along with contaminating bands of 







Another Gelatin Sepharose Chromatography was performed for other batches of P4 
viral stock of the truncated variant following the same affinity purification procedure. 
Aliquots of different purification steps along with eluted protease were subjected to 
another Gelatin Zymography. Analysis of the zymography results revealed that even 
though 1 M NaCl removed a lot of unspecific proteases from the Sepharose column, 
still the aliquots of last wash without NaCl contained large amount unspecific 
proteases (Fig. 24). The observations of both zymography results (Fig. 23 and 24) of 
aliquots from various steps of Gelatin Sepharose purification technique depicted that 
the different sizes of contaminating bands including around 60 kDa, 120 kDa also bind 
to Gelatin Sepharose column and as they also occurred in the last washing step it 
 
Figure 23. Gelatin Zymography showing the gelatin degrading proteases in 
various steps of affinity purification technique. All samples were 200x diluted except 
the aliquot from last wash of purification step. Lane 1-3 represent aliquots of purification 
steps of the truncated proMMP-9 (MMP-9ΔH-HPX) whereas lane no (4-6) represent 
aliquots of purification steps of positive control samples (proMMP-9). An arrow indicates 
the expected MMP-9ΔH-HPX protease in the partly purified sample. 
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might be possible to remove these impurities by introducing further washing steps of 




Identification of the types of protease produced by the 
transfected Sf9 cells 
Before going through additional purification procedure, it was necessary to explore 
what type of protease (metallo-, serine-, and cysteine protease) that was produced by 
the transfected Sf9 cells. The P4 viral stock containing proMMP-9ΔH-HPX was 
 
Figure 24. Gelatin degrading proteases in the aliquots of different steps of affinity 
purification. All samples were 100x diluted. In the lane 1, the molecular standard MMP-
9/2 whereas lane no 2 represents the P4 viral stock containing the truncated proMMP-9. 
The aliquots of Flow through in the lane no 3 and wash with 1 M NaCl in lane no 4. 
Aliquots of the last wash without NaCl is shown in the lane no 5. Purified truncated 
proMMP-9 was collected in different fractions is represented by lane no 6-10. Trypsin is 
in the lane no 11. An arrow indicates the expected proMMP-9ΔH-HPX protease.  
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analysed by Gelatin Zymography together with a MMP-9/2 standard and trypsin as 
controls. After electrophoresis, the gel was cut into four pieces where each piece 
contained P4 viral stock (proMMP-9ΔH-HPX), molecular standard MMP-9/2 and 
trypsin. Thereafter, three pieces were treated separately with three different inhibitors, 
EDTA, E64, and pefabloc during the incubation and washing steps of zymography gel, 
while one piece of the gel was without any inhibitor in the incubating and washing step. 
The zymography result showed that in the control without any inhibitors, gelatin was 
digested by the gelatinolytic enzymes produced as previously seen in the transfected 
Sf9 cells. Additionally, the molecular standard MMP-9/2 and trypsin also digested 
gelatin as expected as there was no inhibitor added to influence the gelatinolytic 
activity (Fig. 25A). In contrast, the presence of the metalloprotease inhibitor EDTA (10 
mM) showed almost complete eradication of the gelatinolytic activity both of the 
proteases produced by the Sf9 cells and the molecular standard MMP-9/2. Since 
trypsin is not a metalloprotease, but a serine protease, it was not affected (Fig. 25B). 
This finding confirmed that the proteases produced by the transfected Sf9 cells were 
all metalloproteases. Cysteine proteases may also have gelatinolytic activity. Using 
the cysteine inhibitor E-64 (5 mM) there was no noticeable effect on the gelatinolytic 
activity of proteases (Fig. 25C), indicating that none of the detected gelatin degrading 
proteases are cysteine proteases. Furthermore, Pefabloc (1mM) which inhibits serine 
proteases like trypsin, showed no inhibition of the protease in the Sf9-sample (Fig. 
25D), but completely eradicated the trypsin activity. Therefore, the gelatin degrading 







Identification of proMMP-ΔH-HPX by Western blot 
To further analyse the produced proMMP-9ΔH-HPX and its molecular mass, Western 
blot under non-reducing condition (right half), and for investigation the dimerization 
patterns if any, a reducing condition (left half) with 0.5 M DTT was carried out. For 
identification of proteases produced by Sf9 cells, reducing condition was preferred 
because DTT usually can dissociate the S-S bridges in the dimer or multimeric form 
of MMP-9. An anti-MMP-9 polyclonal antibody against purified proMMP-9 from THP-1 
cells (1:2000 dilution of 5.1 mg/ml) was used as a primary antibody and a goat anti-
rabbit IgG tagged with Horse Reddish Peroxidase as a secondary antibody (1:1000 of 
1 mg/ml) were used to identify any MMP-9 protease in the blot, including the proMMP-
9ΔH-HPX. ProMMP-9 is known to be produced as a monomer, as well as a variety of 
dimeric forms (Goldberg et al., 1992; Winberg et al., 2000b).The homo- and several 
hetero-dimer forms are SDS-resistant (Triebel et al., 1992a; Van den Steen, 2006) but 
reduction-sensitive (Malla et al., 2008). Under reducing conditions, DTT dissociates 
the S-S bridges in the dimer or multimer of the enzyme which are SDS resistant (Van 
 
Figure 25. Detection of the type of proteases produced in Sf9 cells by using 
inhibitors. The P4 viral stock in the zymography was 200x diluted.  A. Control showing 
the gelatinolytic activity of protease in the absence of inhibitors. B. The presence of 
metalloprotease inhibitor EDTA (10 mM). C. The presence of the Cysteine protease 
inhibitor E-64 (3.2 mM). D. The presence of the serine protease inhibitor pefabloc (0.5 
M) only affected Trypsin activity on gelatin. The arrows in the figure indicates the 




den Steen, 2006). Samples in lane 1-5 were treated with 0.5 M DTT (reducing 
conditions) while the same samples lanes 7-12 were untreated (non-reducing 
conditions) (Fig. 26). Analysis of the Western blot revealed the protein around 48 kDa 
was recognized by the specific anti-MMP-9 antibody in both reducing and non-
reducing conditions further confirming that the protein is the expected proMMP-9ΔH-
HPX protease.  
 
 
Actually, two important findings were observed from the above investigation; firstly, 
the protease around 48 kDa showed gelatinase activity in zymography analysis was 
 
Figure 26. Western blot analysis of the target and control samples under reduced 
and non-reduced conditions. The technique was performed with anti-MMP-9 
polyclonal antibody as primary antibody and goat anti-rabbit IgG as a secondary 
antibody. The reducing agent was added in the sample are represented from lane 1-6. 
Biotinylated molecular weight standard in lane 1 and 12. Control THP-1 derived MMP-
9 (20x) and MMP-9ΔHPX is shown in the lane no 2 and 3, respectively. Another control 
proMMP-9 in the lane no 4 and MMP-9ΔH-HPX containing sample is represented by 
lane no 5. Sample buffer (5x) with (0.5 M) DTT and without DTT is shown in the lane no 
6 and 11, respectively. 
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also recognized by MMP-9 specific antibody in the immuno-blotting. Secondly, besides 
the target size 48 kDa proMMP-9ΔH-HPX, other bands of large molecular weight were 
also identified by anti-MMP-9 antibody raising the question of oligomerization by 
proMMP-9ΔH-HPX. However, the study by Van den Steen et. al. showed that 
proMMP-9ΔH-HPX do not form homo-dimer in contrast to deletion variants of 
proMMP-9 containing the hinge region. Further investigations are needed to determine 
if these high molecular weight proteins indeed are dimers or complexes of proMMP-
9ΔH-HPX. 
Unexpectedly, in the present study the result of immune-blotting of the SDS-gel under 
reduced condition was ambiguous. It was so, because the purified sample was 
concentrated by vacuum centrifuging, resulting in a high concentration of salt in the 
samples made the samples very sticky. Therefore, the sample could not travel properly 
on the gel thereby leaving an inconclusive identification with respect to 
oligomerization.  
In contrast, a single band of the control proMMP-9ΔHPX was recognized by the MMP-
9 antibody under reducing conditions while it was detected as both a monomeric and 
a dimeric form under non reducing conditions. Control THP-1 derived proMMP-9 
showed monomeric form at 92 kDa and a homo-dimer around 200 kDa that was 
reduction sensitive (Fig. 26) as expected from the previous studies (Malla et al., 2013; 
Winberg et al., 2000).  
In the present study, Polyclonal primary antibody was used instead of monoclonal 
antibody in the western blot experiments because polyclonal antibody allows for more 
efficient detection by recognizing multiple epitopes on any one antigen and hence 
amplifying the signal from the target. In addition, it is more tolerant to small changes 
of the protease, such as denaturation. Conversely, polyclonal antibody has higher 





SDS-PAGE of partly purified concentrated proMMP-9ΔH-HPX 
protease 
Zymography is a very sensitive detection method, so to be able to detect the proteins 
on SDS-PAGE and Coomassie staining, the samples need to be concentrated. The 
sample containing partly purified proMMP-9ΔH-HPX protease was concentrated by 
using a spin column with a cut off of 10 kDa before performing SDS-PAGE. One 
hundred (100) µl of proMMP-9ΔH-HPX protease sample was span downed to 20 µl. 
The samples were washed with 300 µl of 0.1 M HEPES washing buffer during the 
concentrating procedure in order to remove DMSO from the sample. The protein 
concentration of the concentrated samples was then determined by NanoDrop 
Spectrophotometer at A280nm. Using Beer-Lambert equation, proMMP-9ΔH-HPX 
enzyme was estimated to be 430 µM. The SDS-PAGE under non-reduced conditions 
(NuPAGE-4-12%, Bis-Tris Gel 1.0 mm x 12 well) was carried out with this 
concentrated partly purified proMMP-ΔH-HPX protease sample. The result of SDS-
PAGE and subsequent Coomassie blue staining revealed a strong band of molecular 
size of around 50 kDa as expected to be our target size protease. Additionally, other 
two contaminating strong bands around 125 kDa and 120 kDa was also present in the 
sample. Two other contaminating weak bands around 70 kDa and 60 kDa was also 
observed in the sample. The intensity of the bands revealed that the 50 kDa band and 
the other two contaminating bands at 125 kDa and 120 kDa was present abundantly 





Western blot analysis of the partly purified concentrated 
proMMP-9ΔH-HPX sample 
For the confirmation of the production of proMMP-9ΔH-HPX protease, the 
concentrated sample containing target protease was subjected to Western blot again 
under non-reducing conditions with anti-MMP-9 polyclonal antibody (1:2000 dilution of 
5.1 mg/ml) as primary antibody and goat anti-rabbit IgG linked with Horse Reddish 
Peroxidase as a secondary antibody (1:1000 of 1 mg/ml). The finding of western blot 
resembled the result of SDS-PAGE in detecting one strong band at 48 kDa and two 
other strong bands and two weak bands contaminating in the purified proMMP-9ΔH-
HPX protease sample (Fig. 28). In previous western blot result (Fig. 26), the 48 kDa 
protease band was observed to be stronger than the other contaminating bands. The 
same findings also revealed by the present western blot analysis.  
 
Figure 27. SDS-PAGE analysis of the partly purified concentrated 
sample containing proMMP-9ΔH-HPX protease. The molecular 
standard Multi-colour high range protein ladder was used in the lane no 1. 
Purified concentrated proMMP-9ΔH-HPX protease sample was used in 







Pufication of MMP-9ΔH-HPX proteinase by Gelatin Sepharose 
Chromatography with an extra washing step 
In order to remove the contaminating high molecular weight proteins, an extra washing 
step was introduced. Previously we used 1.5 ml washing buffer with 1 M NaCl in the 
affinity chromatography to purify the protease from 1 ml P4 viral stock medium. We 
found that this amount was not enough to purify the protease of interest. Therefore, 
we decided to wash the sample with a double volume (3 ml) of washing buffer keeping 
the concentration of NaCl unchanged. During the chromatography, aliquots of the 
different steps in the purification were collected and together with the eluted proMMP-
9ΔH-HPX they were subjected to gelatin zymography. The result of the zymography 
depicted that the eluted proMMP-9ΔH-HPX sample still contained two strong protease 
bands of large molecular weight of 125 and 120 kDa having gelatinase activity even 
 
Figure 28. Identification of proMMP-9ΔH-HPX by western blot. Biotin-labelled 
molecular weight standard was used in the lane no 1. Purified concentrated 
proMMP-9ΔH-HPX in the lane no 2. Arrow in the figure indicates the expected 
proMMP-9ΔH-HPX protease in the sample. 
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though the extra wash with NaCl removed a lot of unspecific proteins from the column. 
Due to a possible overflow in lane 7 from lane 6, it was difficult to determine whether 
the two bands in the region of 62-72 kDa was removed before the last washing step 




From this figure 29 it can be observed that the two contaminating bands around 70 
and 60 kDa were mostly non-specifically bound proteins. Hence these were removed 
abundantly in the washing step. 
The partly purified protease was subjected to a concentration procedure to 
concentrate the protease that were larger than 10 kDa. To do so, a spin column with 
a cut off of 10 kDa was used. The concentrated sample containing proMMP-9ΔH-HPX 
was then used for Gelatin Zymography and found that the purified samples still 
contained several protease bands having gelatinolytic activity. However, 100x dilution 
of the partly purified concentrated proMMP-9ΔH-HPX sample showed larger amounts 
 
Figure 29. Gelatin degrading proteases in eluted fractions and in aliquots of 
double washing steps. All samples were 100x diluted. Lane no 1 shows MMP-
9/2 molecular standard and un-purified P4 viral stock solution in the lane no 2. 
Between the protease samples, 5x sample buffer was used. Aliquots of extra 
washing step with NaCl and last wash is represented by the lane no 6 and 7, 
respectively. Eluted protein fractions are shown by lane no 8-10. An arrow shows 
the proMMP-9ΔH-HPX protease in the sample. 
92 
 
of the 48 kDa proteases than of the contaminating proteases (Fig. 30). The 
concentrated proMMP-9ΔH-HPX sample was determined again using NanoDrop 
Spectrophotometer at A280nm. Using Beer-Lambert equation, the protein concentration 
of the proMMP-9ΔH-HPX sample was estimated to be 1.09 mM. 
 
 
Determining the sizes of proteases removed by additional 
purification step 
In order to see what proteases had been removed by the double washing step, the 
partly purified concentrated sample was subjected to SDS-PAGE. For comparing the 
purification efficacy an un-purified sample containing the target protease proMMP-
9ΔH-HPX was also included in this investigation.  
 
 
Figure 30. Gelatin degrading proteases purified with additional 
washing step of affinity chromatography. Molecular standard MMP-9/2 
and Trypsin is represented by lane no 1 and 3, respectively. The control 
proMMP-9 produced in Sf9 cells is represented by the lane 2. The eluted 
MMP-9ΔH-HPX protease with two dilution 50x and 100x are represented 
by lane no 4 and 5, respectively. The expected proMMP-9ΔH-HPX 




Analysing the image of SDS-PAGE, it was found that the sample of proMMP-9ΔH-
HPX protease that was purified with double washing volume contained three strong 
protease bands and two very weak bands. In contrast, un-purified proMMP-9ΔH-HPX 
protease sample contained several additional bands (Fig. 31). Additional washing was 
found effective to remove most of the two weak contaminating protein bands from the 
target sample. We still need to separate two strong contaminating protease bands of 
larger molecular size around 120 and 130 kDa from the sample.  
 
 
Figure 31. Determining the size of proteases purified with the double washing 
purification step. P-250 kDa protein ladder was used as a molecular standard and both 
purified concentrated proMMP-9ΔH-HPX protease sample and un-purified proMMP-
9ΔH-HPX sample were used in this technique to observe the proteases removed in the 
extra washing step of purification technique. The expected proMMP-9ΔH-HPX protease 





Accurate determination of the molecular weight of proMMP-
9ΔH-HPX protease bands 
For estimating the molecular weight of both purified and un-purified proMMP-9ΔH-
HPX protease bands from SDS-PAGE gel (Fig 31), and from zymography gel (Fig. 30) 
the relative migration distance (Rf) of the standards and proMMP-9ΔH-HPX bands 
were determined by dividing the migration distance of the protein by the migration 
distance of the dye front. A ruler (in centimetre) was used to measure the migration 
distance from the top of the gel for all target bands in the gel (Fig. 32A and B). By 
plotting the molecular weight of each band of the standard in Y axis and the Rf value 
obtained for the bands of the standard on the X axis using a semi logarithm sheet, a 
linear plot was generated. From the graph, the molecular weight of band 1 in the 
purified proMMP-9ΔH-HPX sample was determined to be 125 kDa, band 2 was 
calculated to be 120 kDa, and band 3 to be 48 kDa. The molecular weight of purified 
proMMP-9ΔH-HPX in zymography gel was also determined to be around 48 kDa. The 
molecular size of all detected protein bands in both purified as well as the crude 
samples in SDS-PAGE are summarised in figure 32B. In order to compare the 
molecular weight obtained manually from the semi logarithm sheet, the obtained data 
was plotted in to the computer program Sigma Plot. Here, the molecular size was only 
calculated for the target band of purified proMMP-9ΔH-HPX protease. The calculation 
resulted in a log value 1.69 for the molecular size of the target protease which 
corresponds to 48.9 kDa (Fig. 32A). Since both ways of calculating the molecular size 
of the smallest band gave a size of approximately 48 kDa, we expected that the 











Identification of MMP-9 derived peptides in the proMMP-
9ΔH-HPX sample by MS/MS 
In order to analyse the identity of the proteins in both the 48 kDa band and the 120 
and 125 kDa contaminating bands, the three bands in the SDS-PAGE gel (numbered 
1, 2, and 3 in the figure 31) were cut out for Mass spectrometry (MS) analysis. The 
MS was performed by Tromsø University Proteomics Platform (TUPP). The samples 
 
 
Figure 32. Determination of the molecular size of proMMP-9ΔH-HPX protease 
and contaminating bands from SDS-PAGE (gel 15). A. Sigma plot shows the log 
value for the target smallest band of partly purified proMMP-9ΔH-HPX B. Table 
showing the Rf value and molecular size calculated for the molecular standard as well 




were digested by trypsin and subjected to MS-MS and the various sizes of separated 
peptides are analysed by computer technology using a database for protein 
identification and characterisation based on best matching peptide sizes of theoretical 
trypsin digests of proteins in the database and the investigated protein sample. We 
received the percentage of peptide sequence coverage for three bands from TUPP. 
According to their analysis, band number one (1) showed similarities to seven different 
type of proteins. The top listed protein was MMP-9 and it had 24% similarity of 
database MMP-9 peptide sequence within 366 peptide sequences.  Band number two 
(2) showed similarity to 29 different proteins on the hit list. The highest score belonged 
to human keratin type II with 23% sequence similarity. The analysis of band three (3) 
showed peptide similarity with five proteins of which MMP-9 of Homo sapiens was on 




Figure 33. Mass spectrometry analysis of band number 1 from SDS-PAGE 
showing 24% peptide similarity with full length proMMP-9. Peptide similarity 
is represented by bold red colour.  
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Since we introduced a stop codon at the start of the hinge region our expected C-
terminal end residue is P447. Additionally, our expected protease does not include the 
19 amino acid of pre-domain since that is cleaved off in the ER. Therefore, total amino 
acid residue for the target protease was expected to be 428 instead of 707 amino 
acids for full length proMMP-9. The total amino acid labelled in red for band no 1 in 
the figure 33 was counted to be 170. For estimation of actual percentage of peptide 
similarity, we divided the total labelled amino acid by total amino acid of truncated 
proMMP-9 (170/428) and multiplied by 100. Thus the actual peptide sequence 
coverage appeared to be 40% for the band number 1. From the analysis of MS, it was 
also detected that peptide similarity was within the first 366 amino acids indicating that 
the contaminating band number one (1) could contain the truncated variant proMMP-
9ΔH-HPX. It could be and SDS-stable and reduction stable homodimer or a heteromer 
with unknown partner. 
The second highest score for band 2 showed 16% similarity with full length human 
proMMP-9 (Fig. 34) and 27% similarity if we only compare it with 428 amino acids in 
the truncated human proMMP-9. Here, peptide similarity was detected within first 384 
amino acids of the sequence. As for the contaminating protein band number one, we 
cannot exclude that the contaminating protein band number two also is and SDS-






 2.a. Keratin, type II cytoskeletal 1(Homo sapiens) 
 





Figure 34. Mass spectrometry analysis of band number 2 from SDS-PAGE.  2a 
represents the peptide sequence matched with Keratin, type II cytoskeletal 1 whereas 




Band no 3 showed 46% peptide sequence similarity with human proMMP-9 if we only 
count the 428 amino acids in proMMP-9ΔH-HPX (Fig. 35). All identified peptides 
matched proMMP-9 within the first 447 amino acids which corresponds to the part of 
proMMP-9 included in the produced truncated proMMP-9.  
Based on the above findings, it can be said that bands number 1 and 2 might be a 
homodimers or heteromeric forms of proMMP-9ΔH-HPX that is not reduction sensitive. 
The band number three (3) appeared as proMMP-9ΔH-HPX with maximum peptide 
similarity and the peptide similarity was observed within first 447 amino acids. 
Therefore, we conclude that band number three is our expected monomeric form of 
the proMMP-9ΔH-HPX protease. 
 
3. Matrix metalloproteinase-9 (Homo sapiens) 
 
Figure 35. Mass spectrometry analysis of band number 3 from SDS-PAGE. 





Gelatin Sepharose Chromatography with a pre-elution step 
Although the 125 and 120 kDa bands were shown to contain MMP-9, their exact 
identity is unknown. Thus, further attempts were done to remove both the 125 and the 
120 kDa proteins from the 48 kDa pro MMP-9ΔH-HPX. Various hydrophobic 
compounds such as DMSO (Murphy, 1995.; Strongin et al., 1993), Brij-35 (0.05%), 
and triton X-100 (0.5%) have been previously used for elution of MMP-9 (Malla et al., 
2008). A study revealed that 5% DMSO was able to separate proMMP-9 from gelatin 
(Fini et al., 1991). Additionally, MMP-9 has also been observed to elute with increasing 
concentration of up to 10% DMSO in the presence of 0.05% Brij-35 when it is in 
monomeric form, but at a lower DMSO concentration when it is in a heteromeric form 
(Malla et al., 2008). Hence, we introduced a pre-elution step in the purification protocol 
of the Gelatin Sepharose affinity chromatography, where this step contained the 
elution buffer, bit instead of 7.5% DMSO the buffer contained 0.1% DMSO. Gelatin 
zymography revealed that the proteinase eluted with 0.1% DMSO contained large 
amount MMP-9 protease of molecular sizes of 48 kDa, 62 kDa, and also 72 kDa 
respectively. Those sizes of protease were also removed in huge amount after 
additional wash with NaCl (Fig. 36) indicating that large amount of protease bands of 
those sizes were loosely bounded to gelatin. Additionally, the 125 kDa size protease 
was observed to be eluted in 7.5% DMSO which was also removed by NaCl in large 
amount. From the above observations, we concluded that even though huge amount 
of loosely bound proteins was removed in various steps of the purification technique, 
still eluted protease sample contained two contaminating proteases around 125 kDa 












SDS-PAGE analysis of proteases purified with a pre-elution 
purification step 
Analysis of SDS-PAGE of eluted protease showed the expected 48 kDa protease 
bands along with two strong contaminating bands (Fig. 37). These three bands were 
also observed in the previous SDS-PAGE (Fig. 31) indicating that the pre-elution step 
with 0.1% DMSO was not an effective step to remove the two contaminating bands 
around 120 and 130 kDa from the column. We therefore tested if it was possible to 
remove these two contaminating bands form the 48 kDa target protease by size 
exclusion chromatography. 
 
Figure 36. Gelatin degrading proteases purified with a pre-elution step of affinity 
chromatography.  Additional pre- elution step was performed with elution buffer 
containing 0.1% DMSO. Molecular standard MMP-9/2 in the lane no 1 and 100x diluted 
un-purified protease sample in the lane no 2. 5x sample buffer was loaded in between 
the protein samples. Flow through and wash with NaCl is represented by lane no 4 and 
6, respectively. The protease pre-eluted with 0.1% DMSO in the lane no 9 and protease 
eluted with 7.5% DMSO is resented by lane 11. An arrow indicates the 48 kDa proMMP-






Size exclusion chromatography for purification of the 48 kDa 
proMMP-9ΔH-HPX protease 
Gel filtration chromatography is a technique used for separation of chemical 
substances by size, based on their migration through a stationary bed of porous 
Sephadex gel. 
 
Determination of the separation properties of Sephadex G-75 column  
Before doing the experiment with our protease sample, the separation properties of 
the Sephadex G-75 column was determined by using Blue dextran 2000 (2 mg/ml) 
 
Figure 37. SDS-PAGE showing proMMP-9ΔH-HPX protease eluted after a pre-
elution purification step. Molecular weight standard P-250 kDa protein ladder was 
used to determine the sizes of protease bands present in the sample containing 




and potassium dichromate (0.6 mg/ml). A 10 ml pipet was filled with 6 ml Sephadex 
gel carefully avoiding air bubble. After washing and equilibrating the column with 0.1 
M Hepes buffer, CaCl2, pH 7.5, the Void volume (V0) was determined by blue dextran 
and total volume (Vt) by potassium dichromate. Blue dextran came out between 2.5-4 
ml with a peak at 3 ml. This is the void volume of the column (V0). Potassium chromate 
came out from the column in 4-5 ml with a peak at 4.5 ml. This determines the total 
volume (Vt) of the column.  
 
Separation of target size MMP-9ΔH-HPX (48kDa) using Sephadex G-75 
size exclusion chromatography 
In an attempt to separate the 48 kDa proMMP-9ΔH-HPX from the two contaminating 
proteases with molecular size of 120 kDa and 125 kDa, 100 µl of partly concentrated 
purified proMMP-9ΔH-HPX from Gelatin Sepharose Chromatography was applied to 
the Sephadex G-75 column. It was expected that the contaminating proteases should 
occur in the void volume and the 48 kDa proMMP-9ΔH-HPX should be eluted after the 
void volume. The first 1.5 ml solution was discarded and then the solution was 
collected in 500 µl fractions up to 8 ml. A Gelatin Zymography was performed on the 
eluted fractions using aliquots diluted 25x to explore at what volumes the 48 kDa 
protease could be found. Gelatin Zymography revealed that our 48 kDa proMMP-9ΔH-
HPX came out of the column between 2.5 and 7 ml (Fig. 38, lane 4-13). The 48 kDa 
proMMP-9ΔH-HPX came out of the column already in the void along with other 
contaminating proteases, suggesting that a part of proMMP-9ΔH-HPX has occurred 

















In order to verify the purity of the 48 kDa proMMP-9ΔH-HPX that occurred in the 
fractions after the void volume, fractions 6-8 contained the highest protease activity 
(Fig. 38) were pooled together. This pooled fraction was subjected to SDS-PAGE 
under reducing and non-reducing conditions. A single band of around 48 kDa was 
observed under both reducing and non-reducing conditions (Fig. 39). Thus, we could 
then conclude that we were able to separate the expected 48 kDa protease from the 




Figure 38. Gelatin Zymography showing gelatin degrading proteases in the eluted 
fractions in Sephadex G-75 size exclusion chromatography. 25x diluted purified 
sample containing proMMP-9ΔH-HPX was used for the Zymography. The molecular 
weight standard MMP-9/2 is in the lane 1. Lane 2, 3, show only Hepes buffer. The 
expected protease came out at 2.5 ml solution along with other larger molecules. The 
pure 48 kDa proMMP-9ΔH-HPX protease came out of the column is shown in the 
following elution fractions. The 48 kDa proMMP-9ΔH-HPX protease is indicated by an 








In conclusion, a diagram is outlined to show all the techniques used in the present 
study to produce and purify the recombinant proMMP-9ΔH-HPX. The analytical tools 
used for verifying the production, activity and purity of proMMP-9ΔH-HPX was also 
summarized in the diagram. 
 
Figure 39. SDS-PAGE analysis of purified 48 kDa proMMP-9ΔH-HPX protease. A. 
Under reducing condition a single 48 kDa protease was detected and B. Under non- 
reducing condition the same 48 kDa protease was also detected. Protein marker P-250 
kDa was used to estimate the molecular size of purified protease. The expected 48 kDa 




Figure 40. A diagram summarizing the different steps of proMMP-9ΔH-HPX 






















In conclusion, we were able to produce and purify the expected 48 kDa proMMP-9ΔH-
HPX protease, however in small quantity. The identity of the protease was confirmed 
by Western blot with an anti-MMP-9 antibody and by Mass spectrometry. The activity 
of the protease was confirmed by Gelatin Zymography. The purity of the expected 




Even though at the end of the current project we were able to produce purified 
proMMP-9ΔH-HPX protease in Sf9 insect cells, the yield of the purified protease was 
not sufficient for further investigations. Therefore, the purification procedure needs to 
be optimized for large scale proMMP-9ΔH-HPX production.  
 
Since full length MMP-9 has numerous roles in both physiological and pathological 
conditions, the truncated MMP-9ΔH-HPX in combination with full length MMP-9 can 
be useful in studying these conditions in vitro. The MMP-9ΔH-HPX protein can also 
be used to explore the influence of the hinge and the hemopexin domain on cleavage 
of a number of known substrates of MMP-9 since both domains contain secondary 
binding sites (exosites) for many substrates. TIMP-1 is known to bind to the C-terminal 
hemopexin domain and play significant role in MMP-9 activation (O’Connell et al., 
1994). The deletion variant can be used to study the binding sites of the TIMP-1. 
 
MMP-9 is found to bind to the low-density lipoprotein receptor-related protein-1(LRP-
1) and to the membrane bound receptor, the DNA repair protein Ku by hemopexin 
domain (Monferran et al., 2004). In addition, the hinge region has been shown to be 
involved in proper orientation of the hemopexin domain (Van den Steen, 2006). 
Therefore, the deletion variant of proMMP-9 can be used for more detailed studies of 
the role of the hemopexin domain and hinge region in endocytosis of MMP-9. Full 
length MMP-9 is involved in many physiological process such as cell migration, wound 
healing, tissue remodelling etc. Using the MMP-9ΔH-HPX protease, the role of the 
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A1. Nucleotide sequences of proMMP-9ΔH-HPX aligned with wild type proMMP-
9 by three different primers (mutated nucleotide was outlined in red colour) 
 
 


























































A2. The recombination region of the recombinant BaculoDirect™Baculovirus C-
term linear DNA. LR recombination reaction between Baculovirus linear DNA and 
preproMMP-9ΔH-HPX resulted in recombinant Baculovirus containing preproMMP-
9ΔH-HPX in the genome. Shaded region corresponds to the DNA sequence 
transferred from pDNOR221- preproMMP-9ΔH-HPX whereas the non-shaded region 
denote Baculovirus C-terminal linear DNA. LR product expected to include the 
nucleotides from the polyhedron forward primer binding site to and V5 reverse priming 
site including nucleotide sequence of preproMMP-9ΔH-HPX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
